Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],283,2102,DB00468,Quinine
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],349,2103,DB00468,Quinine
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],98.0,2104,DB00468,Quinine
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],79.8,2105,DB00468,Quinine
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],435,2106,DB00468,Quinine
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],370,2107,DB00468,Quinine
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],34.8,2108,DB00468,Quinine
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],76.5,2109,DB00468,Quinine
,9174284,flow-rate,"The mobile phase was a mixture of 0.1 M sodium acetate in 0.001 M tetrabutylammonium phosphate solution (pH 6) and methanol (30:70, v/v) at a flow-rate of 4 ml/min.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),[ml] / [min],4,2233,DB00468,Quinine
,9174284,retention times,"Under these conditions, no interference in the assay from any endogenous substance or other concurrently used drugs was observed and the retention times of I.S. and TAM were 4.4 and 10.15 min, respectively.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),min,4.4,2234,DB00468,Quinine
,9174284,retention times,"Under these conditions, no interference in the assay from any endogenous substance or other concurrently used drugs was observed and the retention times of I.S. and TAM were 4.4 and 10.15 min, respectively.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),min,10.15,2235,DB00468,Quinine
,9174284,peak height ratio (TAM/I.S.),"The concentration of TAM in plasma was linearly (r>0.9983) related to the peak height ratio (TAM/I.S.) in the range 0.01-2.0 microg ml(-1) and C.V. at 0.075, 0.4 and 1.2 microg ml(-1) was < or = 4.96%.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),[μg] / [ml],0.01-2.0,2236,DB00468,Quinine
,9174284,C.V.,"The concentration of TAM in plasma was linearly (r>0.9983) related to the peak height ratio (TAM/I.S.) in the range 0.01-2.0 microg ml(-1) and C.V. at 0.075, 0.4 and 1.2 microg ml(-1) was < or = 4.96%.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),[μg] / [ml],0.075,2237,DB00468,Quinine
,9174284,C.V.,"The concentration of TAM in plasma was linearly (r>0.9983) related to the peak height ratio (TAM/I.S.) in the range 0.01-2.0 microg ml(-1) and C.V. at 0.075, 0.4 and 1.2 microg ml(-1) was < or = 4.96%.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),[μg] / [ml],0.4,2238,DB00468,Quinine
,9174284,C.V.,"The concentration of TAM in plasma was linearly (r>0.9983) related to the peak height ratio (TAM/I.S.) in the range 0.01-2.0 microg ml(-1) and C.V. at 0.075, 0.4 and 1.2 microg ml(-1) was < or = 4.96%.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),[μg] / [ml],1.2,2239,DB00468,Quinine
<,9174284,C.V.,"The concentration of TAM in plasma was linearly (r>0.9983) related to the peak height ratio (TAM/I.S.) in the range 0.01-2.0 microg ml(-1) and C.V. at 0.075, 0.4 and 1.2 microg ml(-1) was < or = 4.96%.",Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174284/),%,4,2240,DB00468,Quinine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,144,2241,DB00468,Quinine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,80,2242,DB00468,Quinine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,104,2243,DB00468,Quinine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,225,2244,DB00468,Quinine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,8040,2245,DB00468,Quinine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,861,2246,DB00468,Quinine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,1176,2247,DB00468,Quinine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,6531,2248,DB00468,Quinine
,11127249,peak plasma quinine concentration,"Mean peak plasma quinine concentration in the obese group was significantly lower than that observed in the controls (4.0 +/- 0.8 vs 5.0 +/- 0.3 mg/L, P < 0.01).",Pharmacokinetics of quinine in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127249/),[mg] / [l],4.0,3596,DB00468,Quinine
,11127249,peak plasma quinine concentration,"Mean peak plasma quinine concentration in the obese group was significantly lower than that observed in the controls (4.0 +/- 0.8 vs 5.0 +/- 0.3 mg/L, P < 0.01).",Pharmacokinetics of quinine in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127249/),[mg] / [l],5.0,3597,DB00468,Quinine
,11127249,clearances,"The mean clearances of quinine normalized to the ideal bodyweight (IBW) in the obese and the control groups were not significantly different (0.091 +/- 0.018 vs 0.091 +/- 0.024 L/h/kg IBW, P > 0.05).",Pharmacokinetics of quinine in obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127249/),[l] / [h·kg],0.091,3598,DB00468,Quinine
,11127249,clearances,"The mean clearances of quinine normalized to the ideal bodyweight (IBW) in the obese and the control groups were not significantly different (0.091 +/- 0.018 vs 0.091 +/- 0.024 L/h/kg IBW, P > 0.05).",Pharmacokinetics of quinine in obesity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127249/),[l] / [h·kg],0.091,3599,DB00468,Quinine
,12959282,oral clearance,"The mean (+/- s.d.) oral clearance of quinine in smokers (0.189 +/- 0.075 1 h(-1) kg(-1)) was significantly greater than in non-smokers (0.107 +/- 0.045 1 h(-1) kg(-1) , P < 0.01).",Cigarette smoking enhances the elimination of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959282/),[1] / [h·kg],0.189,6869,DB00468,Quinine
,12959282,oral clearance,"The mean (+/- s.d.) oral clearance of quinine in smokers (0.189 +/- 0.075 1 h(-1) kg(-1)) was significantly greater than in non-smokers (0.107 +/- 0.045 1 h(-1) kg(-1) , P < 0.01).",Cigarette smoking enhances the elimination of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959282/),[1] / [h·kg],0.107,6870,DB00468,Quinine
,12959282,elimination half-life,"The mean elimination half-life of quinine in smokers was 7.5 +/- 1.4 (s.d.) h, significantly shorter (P < 0.005) than the mean value in non-smokers (12.0 +/- 3.1 h).",Cigarette smoking enhances the elimination of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959282/),h,7.5,6871,DB00468,Quinine
,12959282,elimination half-life,"The mean elimination half-life of quinine in smokers was 7.5 +/- 1.4 (s.d.) h, significantly shorter (P < 0.005) than the mean value in non-smokers (12.0 +/- 3.1 h).",Cigarette smoking enhances the elimination of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959282/),h,12.0,6872,DB00468,Quinine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],0.07,6943,DB00468,Quinine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],0.17,6944,DB00468,Quinine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],0.81,6945,DB00468,Quinine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],1.11,6946,DB00468,Quinine
,4061126,Urinary digoxin recovery,"Urinary digoxin recovery rose from 154.0 +/- 18.8 to 181.5 +/- 22.6 micrograms/24 h (p less than 0.01), whereas renal digoxin clearance was unaltered in the presence of quinine (181.5 +/- 24.2 vs. 174.1 +/- 26.5 ml/min).",Effect of quinine on plasma digoxin concentration and renal digoxin clearance. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4061126/),[μg] / [24·h],154.0,8514,DB00468,Quinine
,4061126,Urinary digoxin recovery,"Urinary digoxin recovery rose from 154.0 +/- 18.8 to 181.5 +/- 22.6 micrograms/24 h (p less than 0.01), whereas renal digoxin clearance was unaltered in the presence of quinine (181.5 +/- 24.2 vs. 174.1 +/- 26.5 ml/min).",Effect of quinine on plasma digoxin concentration and renal digoxin clearance. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4061126/),[μg] / [24·h],181.5,8515,DB00468,Quinine
,4061126,renal digoxin clearance,"Urinary digoxin recovery rose from 154.0 +/- 18.8 to 181.5 +/- 22.6 micrograms/24 h (p less than 0.01), whereas renal digoxin clearance was unaltered in the presence of quinine (181.5 +/- 24.2 vs. 174.1 +/- 26.5 ml/min).",Effect of quinine on plasma digoxin concentration and renal digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4061126/),[ml] / [min],181.5,8516,DB00468,Quinine
,4061126,renal digoxin clearance,"Urinary digoxin recovery rose from 154.0 +/- 18.8 to 181.5 +/- 22.6 micrograms/24 h (p less than 0.01), whereas renal digoxin clearance was unaltered in the presence of quinine (181.5 +/- 24.2 vs. 174.1 +/- 26.5 ml/min).",Effect of quinine on plasma digoxin concentration and renal digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4061126/),[ml] / [min],174.1,8517,DB00468,Quinine
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],200,9559,DB00468,Quinine
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],10,9560,DB00468,Quinine
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],25,9561,DB00468,Quinine
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],2.5,9562,DB00468,Quinine
,2049249,ke0,"The mean value of ke0 was 3.32 +/- 5.93 h-1 s.d., for gamma it was 1.73 +/- 1.14 s.d. and for k it was 0.59 +/- 0.66 s.d.",Hearing impairment related to plasma quinine concentration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049249/),1/[h],3.32,11838,DB00468,Quinine
,2049249,gamma,"The mean value of ke0 was 3.32 +/- 5.93 h-1 s.d., for gamma it was 1.73 +/- 1.14 s.d. and for k it was 0.59 +/- 0.66 s.d.",Hearing impairment related to plasma quinine concentration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049249/),d·s,1.73,11839,DB00468,Quinine
,2049249,k,"The mean value of ke0 was 3.32 +/- 5.93 h-1 s.d., for gamma it was 1.73 +/- 1.14 s.d. and for k it was 0.59 +/- 0.66 s.d.",Hearing impairment related to plasma quinine concentration in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049249/),d·s,0.59,11840,DB00468,Quinine
,7408402,total body clearance,Quinine reduced digoxin total body clearance by 26% from 2.98 to 2.22 ml/min/kg (p < 0.03).,Effect of quinine on digoxin kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),[ml] / [kg·min],2,15499,DB00468,Quinine
,7408402,elimination half-life (t 1/2),"Digoxin elimination half-life (t 1/2) was lengthened from 34.2 to 51.8 hr, reflecting a 32% decrease in digoxin elimination rate constant (p < 0.003).",Effect of quinine on digoxin kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),h,34.2,15500,DB00468,Quinine
,7408402,elimination half-life (t 1/2),"Digoxin elimination half-life (t 1/2) was lengthened from 34.2 to 51.8 hr, reflecting a 32% decrease in digoxin elimination rate constant (p < 0.003).",Effect of quinine on digoxin kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),h,51.8,15501,DB00468,Quinine
,7408402,x,29 micrograms to x = 772.52 micrograms (p < 0.02).,Effect of quinine on digoxin kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),μg,772.52,15502,DB00468,Quinine
,7408402,nonrenal clearance,Digoxin nonrenal clearance decreased an average of 55% from 1.2 to 0.55 ml/min/kg (p < 0.05).,Effect of quinine on digoxin kinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),[ml] / [kg·min],1.2,15503,DB00468,Quinine
,7408402,nonrenal clearance,Digoxin nonrenal clearance decreased an average of 55% from 1.2 to 0.55 ml/min/kg (p < 0.05).,Effect of quinine on digoxin kinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),[ml] / [kg·min],0.55,15504,DB00468,Quinine
,30945322,ratio,The quinine/3-OH-quinine ratio decreased from 20.2 (± 13.4) at baseline to 11.0 (± 4.34).,Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30945322/),,20.2,18416,DB00468,Quinine
,30945322,ratio,The quinine/3-OH-quinine ratio decreased from 20.2 (± 13.4) at baseline to 11.0 (± 4.34).,Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30945322/),,11.0,18417,DB00468,Quinine
,3768247,apparent oral clearance,"After cimetidine pretreatment there was a significant reduction in the apparent oral clearance of quinine, from 0.182 +/- 0.063 (mean +/- s.d.) to 0.133 +/- 0.055 1 h-1 kg-1 (P less than 0.05).",Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),[1] / [h·kg],0.182,21822,DB00468,Quinine
,3768247,apparent oral clearance,"After cimetidine pretreatment there was a significant reduction in the apparent oral clearance of quinine, from 0.182 +/- 0.063 (mean +/- s.d.) to 0.133 +/- 0.055 1 h-1 kg-1 (P less than 0.05).",Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),[1] / [h·kg],0.133,21823,DB00468,Quinine
,3768247,elimination half-life,This was reflected in a 49% (range 17 to 90%) increase in the mean elimination half-life from 7.6 +/- 1.3 to 11.3 +/- 3.7 h (P less than 0.05).,Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),h,7.6,21824,DB00468,Quinine
,3768247,elimination half-life,This was reflected in a 49% (range 17 to 90%) increase in the mean elimination half-life from 7.6 +/- 1.3 to 11.3 +/- 3.7 h (P less than 0.05).,Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),h,11.3,21825,DB00468,Quinine
,7570885,fever clearance times,"Mean fever clearance times (+/- standard errors) were 48.6 +/- 2.7 h and 35.9 +/- 2.2 h in the intrarectal and intramuscular groups, respectively (P = 0.05).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,48.6,24035,DB00468,Quinine
,7570885,fever clearance times,"Mean fever clearance times (+/- standard errors) were 48.6 +/- 2.7 h and 35.9 +/- 2.2 h in the intrarectal and intramuscular groups, respectively (P = 0.05).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,35.9,24036,DB00468,Quinine
,7570885,parasite clearance times,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,46.5,24037,DB00468,Quinine
,7570885,parasite clearance times,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,27.4,24038,DB00468,Quinine
,7570885,times to achieve 50% reduction,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,7.8,24039,DB00468,Quinine
,7570885,times to achieve 50% reduction,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,27.4,24040,DB00468,Quinine
,7570885,times to achieve 50% reduction,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,8.7,24041,DB00468,Quinine
,7570885,Cmax,"after intrarectal administration (2.7 +/- 0.4 h) did not differ significantly from the value after intramuscular administration (1.1 +/- 0.6 h), but Cmax.",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,1.1,24042,DB00468,Quinine
,7570885,area under the concentration-time curve from 0 to 48 h,"and the area under the concentration-time curve from 0 to 48 h were lower (4.9 +/- 0.6 mg/L and 230.0 +/- 9.6 mg/L.h, respectively) than after intramuscular administration (9.1 +/- 1.2 mg/L and 356.0 +/- 4.2 mg/L.h, respectively) (P < 0.001).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),[mg] / [h·l],230.0,24043,DB00468,Quinine
,7570885,area under the concentration-time curve from 0 to 48 h,"and the area under the concentration-time curve from 0 to 48 h were lower (4.9 +/- 0.6 mg/L and 230.0 +/- 9.6 mg/L.h, respectively) than after intramuscular administration (9.1 +/- 1.2 mg/L and 356.0 +/- 4.2 mg/L.h, respectively) (P < 0.001).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),[mg] / [h·l],356.0,24044,DB00468,Quinine
,7570885,bioavailability,"Compared to the intramuscular route, intrarectal Quinimax bioavailability was 40%.(ABSTRACT TRUNCATED AT 250 WORDS)",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),%,40,24045,DB00468,Quinine
,19369041,partition coefficient,The QN partition coefficient into infected erythrocytes doubled (6.25+/-0.25) when the drug was nanoencapsulated compared with the free drug (3.03+/-0.07).,Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369041/),,6.25,25495,DB00468,Quinine
,19369041,partition coefficient,The QN partition coefficient into infected erythrocytes doubled (6.25+/-0.25) when the drug was nanoencapsulated compared with the free drug (3.03+/-0.07).,Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369041/),,3.03,25496,DB00468,Quinine
,9020396,fractional excretion of paraquat (FEpq),The fractional excretion of paraquat (FEpq) decreased from 2.1+/-0.01 to 1.2+/-0.03 as the plasma concentration rose from 0.4+/-0.02 to 21.2+/-1.6 microM.,The mechanism of excretion of paraquat in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),,2.1,27289,DB00468,Quinine
,9020396,fractional excretion of paraquat (FEpq),The fractional excretion of paraquat (FEpq) decreased from 2.1+/-0.01 to 1.2+/-0.03 as the plasma concentration rose from 0.4+/-0.02 to 21.2+/-1.6 microM.,The mechanism of excretion of paraquat in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),,1.2,27290,DB00468,Quinine
,9020396,Km,"The excretion of PQ was dependent predominantly on the glomerular filtration rate with a small secretory component (Km = 8.5+/-3.1 microM, Vmax = 114+/-19 nmol/kg per min).",The mechanism of excretion of paraquat in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),μM,8.5,27291,DB00468,Quinine
,9020396,Vmax,"The excretion of PQ was dependent predominantly on the glomerular filtration rate with a small secretory component (Km = 8.5+/-3.1 microM, Vmax = 114+/-19 nmol/kg per min).",The mechanism of excretion of paraquat in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9020396/),[nM] / [kg·min],114,27292,DB00468,Quinine
,8706776,tmax,"Absorption was delayed, but increased in CRF (tmax 4.5 vs 1.6 h, Cmax 6.17 vs 3.45 micrograms.ml-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),h,4.5,29579,DB00468,Quinine
,8706776,tmax,"Absorption was delayed, but increased in CRF (tmax 4.5 vs 1.6 h, Cmax 6.17 vs 3.45 micrograms.ml-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),h,1.6,29580,DB00468,Quinine
,8706776,Cmax,"Absorption was delayed, but increased in CRF (tmax 4.5 vs 1.6 h, Cmax 6.17 vs 3.45 micrograms.ml-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[μg] / [ml],6.17,29581,DB00468,Quinine
,8706776,Cmax,"Absorption was delayed, but increased in CRF (tmax 4.5 vs 1.6 h, Cmax 6.17 vs 3.45 micrograms.ml-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[μg] / [ml],3.45,29582,DB00468,Quinine
,8706776,Total clearance,"Total clearance was significantly reduced (0.94 vs 2.84 ml.min-1.kg-1, whereas Vz/f remained unchanged (1.82 vs 2.78 l. kg-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[ml] / [kg·min],0.94,29583,DB00468,Quinine
,8706776,Total clearance,"Total clearance was significantly reduced (0.94 vs 2.84 ml.min-1.kg-1, whereas Vz/f remained unchanged (1.82 vs 2.78 l. kg-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[ml] / [kg·min],2.84,29584,DB00468,Quinine
,8706776,Vz/f,"Total clearance was significantly reduced (0.94 vs 2.84 ml.min-1.kg-1, whereas Vz/f remained unchanged (1.82 vs 2.78 l. kg-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[l] / [kg],1.82,29585,DB00468,Quinine
,8706776,Vz/f,"Total clearance was significantly reduced (0.94 vs 2.84 ml.min-1.kg-1, whereas Vz/f remained unchanged (1.82 vs 2.78 l. kg-1).",Pharmacokinetics of quinine in patients with chronic renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[l] / [kg],2.78,29586,DB00468,Quinine
,8706776,AUC,"This resulted in the increased values of AUC and prolongation of the t1/2z and MRT in the patients (AUC 181.5 vs 61.8 micrograms.min-1.ml-1, t1/2z 26 vs 9.7 h, MRT 36.4 vs 11.3 h).",Pharmacokinetics of quinine in patients with chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[μg] / [min·ml],181.5,29587,DB00468,Quinine
,8706776,AUC,"This resulted in the increased values of AUC and prolongation of the t1/2z and MRT in the patients (AUC 181.5 vs 61.8 micrograms.min-1.ml-1, t1/2z 26 vs 9.7 h, MRT 36.4 vs 11.3 h).",Pharmacokinetics of quinine in patients with chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),[μg] / [min·ml],61.8,29588,DB00468,Quinine
,8706776,t1/2z,"This resulted in the increased values of AUC and prolongation of the t1/2z and MRT in the patients (AUC 181.5 vs 61.8 micrograms.min-1.ml-1, t1/2z 26 vs 9.7 h, MRT 36.4 vs 11.3 h).",Pharmacokinetics of quinine in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),h,26,29589,DB00468,Quinine
,8706776,t1/2z,"This resulted in the increased values of AUC and prolongation of the t1/2z and MRT in the patients (AUC 181.5 vs 61.8 micrograms.min-1.ml-1, t1/2z 26 vs 9.7 h, MRT 36.4 vs 11.3 h).",Pharmacokinetics of quinine in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),h,9.7,29590,DB00468,Quinine
,8706776,MRT,"This resulted in the increased values of AUC and prolongation of the t1/2z and MRT in the patients (AUC 181.5 vs 61.8 micrograms.min-1.ml-1, t1/2z 26 vs 9.7 h, MRT 36.4 vs 11.3 h).",Pharmacokinetics of quinine in patients with chronic renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),h,36.4,29591,DB00468,Quinine
,8706776,MRT,"This resulted in the increased values of AUC and prolongation of the t1/2z and MRT in the patients (AUC 181.5 vs 61.8 micrograms.min-1.ml-1, t1/2z 26 vs 9.7 h, MRT 36.4 vs 11.3 h).",Pharmacokinetics of quinine in patients with chronic renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),h,11.3,29592,DB00468,Quinine
,8706776,concentrations,"Median concentrations of plasma unbound fraction of Qn collected at 4 h after drug administration in patients and healthy subjects were 7.3 vs 9.8%, respectively.",Pharmacokinetics of quinine in patients with chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),%,7.3,29593,DB00468,Quinine
,8706776,plasma unbound fraction,"Median concentrations of plasma unbound fraction of Qn collected at 4 h after drug administration in patients and healthy subjects were 7.3 vs 9.8%, respectively.",Pharmacokinetics of quinine in patients with chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),%,7.3,29594,DB00468,Quinine
,8706776,plasma unbound fraction,"Median concentrations of plasma unbound fraction of Qn collected at 4 h after drug administration in patients and healthy subjects were 7.3 vs 9.8%, respectively.",Pharmacokinetics of quinine in patients with chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706776/),%,9.8,29595,DB00468,Quinine
,8898467,concentrations,"Following a single oral dose, mean plasma quinine concentrations were significantly higher during the acute illness than after recovery (5.2 +/- 0.9 ug/ml versus 3.6 +/- 0.4 ug/ml).",Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8898467/),[ug] / [ml],5.2,32124,DB00468,Quinine
,8898467,concentrations,"Following a single oral dose, mean plasma quinine concentrations were significantly higher during the acute illness than after recovery (5.2 +/- 0.9 ug/ml versus 3.6 +/- 0.4 ug/ml).",Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8898467/),[ug] / [ml],3.6,32125,DB00468,Quinine
,8898467,time to peak plasma concentration,The mean time to peak plasma concentration was 3.9 +/- 09 hour during the acute illness and 1.8 +/- 0.9 hour after convalescence.,Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8898467/),h,3.9,32126,DB00468,Quinine
,8898467,time to peak plasma concentration,The mean time to peak plasma concentration was 3.9 +/- 09 hour during the acute illness and 1.8 +/- 0.9 hour after convalescence.,Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8898467/),h,1.8,32127,DB00468,Quinine
,8898467,volume of distribution,The volume of distribution was 3.0 +/- 0.3 L/kg during the acute illness and 4.9 +/- 1.4 L/kg after convalescence.,Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8898467/),[l] / [kg],3.0,32128,DB00468,Quinine
,8898467,volume of distribution,The volume of distribution was 3.0 +/- 0.3 L/kg during the acute illness and 4.9 +/- 1.4 L/kg after convalescence.,Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8898467/),[l] / [kg],4.9,32129,DB00468,Quinine
,8898467,terminal half-life,The decline in plasma concentration following multiple dosing was monoexponential with a terminal half-life of 12.1 hours.,Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8898467/),h,12.1,32130,DB00468,Quinine
,10456490,Cmax,"The mean Cmax of the metabolite (0.25+/-0.09 mg l(-1), mean +/- SD) while subjects received full-strength grapefruit juice was significantly less than during the control period (0.31+/-0.06 mg l(-1), P < 0.05) and during the intake of half-strength grapefruit juice (0.31+/-0.07 mg l(-1), P < 0.05).",Grapefruit juice has no effect on quinine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456490/),[mg] / [l],0.25,32973,DB00468,Quinine
,10456490,Cmax,"The mean Cmax of the metabolite (0.25+/-0.09 mg l(-1), mean +/- SD) while subjects received full-strength grapefruit juice was significantly less than during the control period (0.31+/-0.06 mg l(-1), P < 0.05) and during the intake of half-strength grapefruit juice (0.31+/-0.07 mg l(-1), P < 0.05).",Grapefruit juice has no effect on quinine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456490/),[mg] / [l],0.31,32974,DB00468,Quinine
,10456490,Cmax,"The mean Cmax of the metabolite (0.25+/-0.09 mg l(-1), mean +/- SD) while subjects received full-strength grapefruit juice was significantly less than during the control period (0.31+/-0.06 mg l(-1), P < 0.05) and during the intake of half-strength grapefruit juice (0.31+/-0.07 mg l(-1), P < 0.05).",Grapefruit juice has no effect on quinine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456490/),[mg] / [l],0.31,32975,DB00468,Quinine
,8471408,fraction available (F),"The mean (+/- s.d.) fraction available (F) was 0.76 (0.11) after both oral doses and maximum plasma drug concentrations occurred at 1.90 (0.83) h and 2.00 (0.30) h, respectively.",The reproducibility of quinine bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471408/),,0.76,35110,DB00468,Quinine
,8471408,maximum plasma drug concentrations,"The mean (+/- s.d.) fraction available (F) was 0.76 (0.11) after both oral doses and maximum plasma drug concentrations occurred at 1.90 (0.83) h and 2.00 (0.30) h, respectively.",The reproducibility of quinine bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471408/),h,1.90,35111,DB00468,Quinine
,8471408,maximum plasma drug concentrations,"The mean (+/- s.d.) fraction available (F) was 0.76 (0.11) after both oral doses and maximum plasma drug concentrations occurred at 1.90 (0.83) h and 2.00 (0.30) h, respectively.",The reproducibility of quinine bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471408/),h,2.00,35112,DB00468,Quinine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],13.2,35751,DB00468,Quinine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],9.7,35752,DB00468,Quinine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],8.9,35753,DB00468,Quinine
,9140510,critical threshold concentration,"For artemisinin, a critical threshold concentration of 3 x 10(-8) M was required for growth inhibition.",Repetitive dosing of artemisinin and quinine against Plasmodium falciparum in vitro: a simulation of the in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140510/),M,3 x 10(-8),37582,DB00468,Quinine
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,7.2 to 15.4,37675,DB00468,Quinine
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,9.4,37676,DB00468,Quinine
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,5.4 to 27.2,37677,DB00468,Quinine
,6540112,Half-life,Half-life of theophylline ranged from 7.2 to 15.4 h (9.4 +/- 4.4 h; mean +/- SD) and that of quinine from 5.4 to 27.2 h (14.4 +/- 9.2 h).,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),h,14.4,37678,DB00468,Quinine
,6540112,Peak concentrations,Peak concentrations of theophylline in the plasma (7.5 +/- 1.6 micrograms/ml) are below those which are thought to produce concentration-dependent side effects.,Plasma concentrations of theophylline and quinine in healthy volunteers following oral administration of a fixed drug combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540112/),[μg] / [ml],7.5,37679,DB00468,Quinine
,27020278,total amounts,"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,217.10,38676,DB00468,Quinine
,27020278,total amounts,"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,199.0,38677,DB00468,Quinine
,27020278,total amounts,"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,126.40,38678,DB00468,Quinine
,27020278,total amounts,"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,135.20,38679,DB00468,Quinine
,27020278,excreted unchanged (Du(∞)),"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,217.10,38680,DB00468,Quinine
,27020278,excreted unchanged (Du(∞)),"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,199.0,38681,DB00468,Quinine
,27020278,excreted unchanged (Du(∞)),"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,126.40,38682,DB00468,Quinine
,27020278,excreted unchanged (Du(∞)),"The total amounts of ampicillin and cloxacillin excreted unchanged (Du(∞)) alone were 217.10 ± 53.82 and 199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ± 52.24 mg, respectively, with quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),mg,135.20,38683,DB00468,Quinine
,27020278,maximum excretion rates (dDu/dt max),Respective maximum excretion rates (dDu/dt max) for ampicillin and cloxacillin were 43.55 ± 19.41 and 77.64 ± 29.65 mg/h alone versus 18.01 ± 8.52 and 53.16 ± 20.72 mg/h with quinine.,Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[mg] / [h],43.55,38684,DB00468,Quinine
,27020278,maximum excretion rates (dDu/dt max),Respective maximum excretion rates (dDu/dt max) for ampicillin and cloxacillin were 43.55 ± 19.41 and 77.64 ± 29.65 mg/h alone versus 18.01 ± 8.52 and 53.16 ± 20.72 mg/h with quinine.,Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[mg] / [h],77.64,38685,DB00468,Quinine
,27020278,maximum excretion rates (dDu/dt max),Respective maximum excretion rates (dDu/dt max) for ampicillin and cloxacillin were 43.55 ± 19.41 and 77.64 ± 29.65 mg/h alone versus 18.01 ± 8.52 and 53.16 ± 20.72 mg/h with quinine.,Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[mg] / [h],18.01,38686,DB00468,Quinine
,27020278,maximum excretion rates (dDu/dt max),Respective maximum excretion rates (dDu/dt max) for ampicillin and cloxacillin were 43.55 ± 19.41 and 77.64 ± 29.65 mg/h alone versus 18.01 ± 8.52 and 53.16 ± 20.72 mg/h with quinine.,Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[mg] / [h],53.16,38687,DB00468,Quinine
,27020278,MIC,"The MIC of antibiotics alone versus with quinine, respectively, were 0.11 ± 0.04 and 0.78 ± 0.1 µg/ml for ampicillin, and 0.18 ± 0.1 and 0.92 ± 0.4 µg/ml for cloxacillin, with a five- to sevenfold increase (p > 0.01); indicating a decrease in antimicrobial activity by quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[μg] / [ml],0.11,38688,DB00468,Quinine
,27020278,MIC,"The MIC of antibiotics alone versus with quinine, respectively, were 0.11 ± 0.04 and 0.78 ± 0.1 µg/ml for ampicillin, and 0.18 ± 0.1 and 0.92 ± 0.4 µg/ml for cloxacillin, with a five- to sevenfold increase (p > 0.01); indicating a decrease in antimicrobial activity by quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[μg] / [ml],0.78,38689,DB00468,Quinine
,27020278,MIC,"The MIC of antibiotics alone versus with quinine, respectively, were 0.11 ± 0.04 and 0.78 ± 0.1 µg/ml for ampicillin, and 0.18 ± 0.1 and 0.92 ± 0.4 µg/ml for cloxacillin, with a five- to sevenfold increase (p > 0.01); indicating a decrease in antimicrobial activity by quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[μg] / [ml],0.18,38690,DB00468,Quinine
,27020278,MIC,"The MIC of antibiotics alone versus with quinine, respectively, were 0.11 ± 0.04 and 0.78 ± 0.1 µg/ml for ampicillin, and 0.18 ± 0.1 and 0.92 ± 0.4 µg/ml for cloxacillin, with a five- to sevenfold increase (p > 0.01); indicating a decrease in antimicrobial activity by quinine.",Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27020278/),[μg] / [ml],0.92,38691,DB00468,Quinine
,10770766,Recrudescence rates,"Recrudescence rates were 16, 38, and 15% for the Q, AQ3, and AQ5 groups, respectively (P < 0.001).",Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770766/),%,16,40011,DB00468,Quinine
,10770766,Recrudescence rates,"Recrudescence rates were 16, 38, and 15% for the Q, AQ3, and AQ5 groups, respectively (P < 0.001).",Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770766/),%,38,40012,DB00468,Quinine
,10770766,Recrudescence rates,"Recrudescence rates were 16, 38, and 15% for the Q, AQ3, and AQ5 groups, respectively (P < 0.001).",Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770766/),%,15,40013,DB00468,Quinine
,10770766,parasite elimination half-life,"Several models were tested, but the best model was a monoexponential decline of the parasitemia in which the mean parasite elimination half-life was shorter after artemisinin (5.1 h; 95% confidence interval [CI], 4.9 to 5.2 h) than after quinine (8.0 h [95% CI, 7.5 to 8.3 h]).",Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770766/),h,5.1,40014,DB00468,Quinine
,10770766,parasite elimination half-life,"Several models were tested, but the best model was a monoexponential decline of the parasitemia in which the mean parasite elimination half-life was shorter after artemisinin (5.1 h; 95% confidence interval [CI], 4.9 to 5.2 h) than after quinine (8.0 h [95% CI, 7.5 to 8.3 h]).",Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770766/),h,8.0,40015,DB00468,Quinine
,11201303,oral bioavailability,"Consequently, the oral bioavailability of quinine was significantly increased (p < 0.05) from 17% (control) to 42% after pretreatment with naringin.",Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11201303/),%,17,41226,DB00468,Quinine
,11201303,oral bioavailability,"Consequently, the oral bioavailability of quinine was significantly increased (p < 0.05) from 17% (control) to 42% after pretreatment with naringin.",Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11201303/),%,42,41227,DB00468,Quinine
,3983356,t 1/2,The rate of quinine elimination was not significantly altered by forced acid diuresis in five patients (t 1/2 25.1 +/- SEM 4.6 h) as compared to eight patients treated conservatively (t 1/2 26.5 +/- SEM 5.78 h).,Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3983356/),h,25.1,41285,DB00468,Quinine
,3983356,t 1/2,The rate of quinine elimination was not significantly altered by forced acid diuresis in five patients (t 1/2 25.1 +/- SEM 4.6 h) as compared to eight patients treated conservatively (t 1/2 26.5 +/- SEM 5.78 h).,Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3983356/),h,26.5,41286,DB00468,Quinine
greater,1763797,peak concentrations,The low-dose intravenous quinine regimen resulted in mean peak concentrations greater than 6 mg/l and mean low concentrations greater than 3.5 mg/l.,Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763797/),[mg] / [l],6,43035,DB00468,Quinine
greater,1763797,low concentrations,The low-dose intravenous quinine regimen resulted in mean peak concentrations greater than 6 mg/l and mean low concentrations greater than 3.5 mg/l.,Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763797/),[mg] / [l],3.5,43036,DB00468,Quinine
,1763797,99% in vitro inhibitory concentration (EC99),"All blood concentrations exceeded the 99% in vitro inhibitory concentration (EC99) of 0.89 mg/l or less of quinine for 60 isolates of Plasmodium falciparum, which were taken from children with malaria during the same period.",Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763797/),[mg] / [l],0.89,43037,DB00468,Quinine
,2060545,acute,In acute malaria plasma concentrations were approximately 50% higher than in convalescence; the mean acute peak plasma quinine concentration was 8.4 mg.l-1 compared to 5.7 mg.l-1 in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[mg] / [l],8.4,43732,DB00468,Quinine
,2060545,acute,In acute malaria plasma concentrations were approximately 50% higher than in convalescence; the mean acute peak plasma quinine concentration was 8.4 mg.l-1 compared to 5.7 mg.l-1 in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[mg] / [l],5.7,43733,DB00468,Quinine
,2060545,peak plasma quinine concentration,In acute malaria plasma concentrations were approximately 50% higher than in convalescence; the mean acute peak plasma quinine concentration was 8.4 mg.l-1 compared to 5.7 mg.l-1 in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[mg] / [l],8.4,43734,DB00468,Quinine
,2060545,peak plasma quinine concentration,In acute malaria plasma concentrations were approximately 50% higher than in convalescence; the mean acute peak plasma quinine concentration was 8.4 mg.l-1 compared to 5.7 mg.l-1 in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[mg] / [l],5.7,43735,DB00468,Quinine
,2060545,time to peak plasma concentration,The mean time to peak plasma concentration was 5.9 h in acute malaria and 3.2 h in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),h,5.9,43736,DB00468,Quinine
,2060545,time to peak plasma concentration,The mean time to peak plasma concentration was 5.9 h in acute malaria and 3.2 h in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),h,3.2,43737,DB00468,Quinine
,2060545,apparent clearance of oral quinine (CL/f),"The apparent clearance of oral quinine (CL/f) during the illness was 1.51 ml.kg-1.min-1, which was significantly lower than in convalescence--2.67 ml.kg-1.min-1.",Disposition of oral quinine in acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[ml] / [kg·min],1.51,43738,DB00468,Quinine
,2060545,apparent clearance of oral quinine (CL/f),"The apparent clearance of oral quinine (CL/f) during the illness was 1.51 ml.kg-1.min-1, which was significantly lower than in convalescence--2.67 ml.kg-1.min-1.",Disposition of oral quinine in acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[ml] / [kg·min],2.67,43739,DB00468,Quinine
,2060545,clearance,Estimated free quinine clearance was also lower in the acute phase: 30.6 compared to 49.0 ml.kg-1.min-1 in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[ml] / [kg·min],30.6,43740,DB00468,Quinine
,2060545,clearance,Estimated free quinine clearance was also lower in the acute phase: 30.6 compared to 49.0 ml.kg-1.min-1 in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[ml] / [kg·min],49.0,43741,DB00468,Quinine
,2060545,plasma protein binding,Mean (SD) plasma protein binding of quinine was 94.7% in acute malaria and 92.8% in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),%,94.7,43742,DB00468,Quinine
,2060545,plasma protein binding,Mean (SD) plasma protein binding of quinine was 94.7% in acute malaria and 92.8% in convalescence.,Disposition of oral quinine in acute falciparum malaria. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),%,92.8,43743,DB00468,Quinine
,2060545,Binding,"Binding was significantly correlated with the plasma concentration of alpha 1 acid glycoprotein (r = 0.5), which was significantly higher in the acute phase; 1.48 g.l-1 compared to 1.05 g.l-1 during convalescence.",Disposition of oral quinine in acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[g] / [l],1.48,43744,DB00468,Quinine
,2060545,Binding,"Binding was significantly correlated with the plasma concentration of alpha 1 acid glycoprotein (r = 0.5), which was significantly higher in the acute phase; 1.48 g.l-1 compared to 1.05 g.l-1 during convalescence.",Disposition of oral quinine in acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060545/),[g] / [l],1.05,43745,DB00468,Quinine
,18510819,AUC(0-24),"Following administration of taste-masked pellets to healthy adult volunteers, peak plasma concentration (C(max)) and area-under-the-curve (AUC) (C(max) 4.7 microg x ml(-1), AUC(0-24) 63.5 microg x h x ml(-1)) were significantly higher (p<0.05) than for tablets (C(max) 3.7 microg x ml(-1), AUC(0-24) 52.4 microg x h x ml(-1)), but still within the limits reported for quinine.",Taste-masked quinine sulphate pellets: bio-availability in adults and steady-state plasma concentrations in children with uncomplicated Plasmodium falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510819/),[h·μg] / [ml],63.5,52220,DB00468,Quinine
,18510819,C(max),"Following administration of taste-masked pellets to healthy adult volunteers, peak plasma concentration (C(max)) and area-under-the-curve (AUC) (C(max) 4.7 microg x ml(-1), AUC(0-24) 63.5 microg x h x ml(-1)) were significantly higher (p<0.05) than for tablets (C(max) 3.7 microg x ml(-1), AUC(0-24) 52.4 microg x h x ml(-1)), but still within the limits reported for quinine.",Taste-masked quinine sulphate pellets: bio-availability in adults and steady-state plasma concentrations in children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510819/),[μg] / [ml],3.7,52221,DB00468,Quinine
,18510819,AUC(0-24),"Following administration of taste-masked pellets to healthy adult volunteers, peak plasma concentration (C(max)) and area-under-the-curve (AUC) (C(max) 4.7 microg x ml(-1), AUC(0-24) 63.5 microg x h x ml(-1)) were significantly higher (p<0.05) than for tablets (C(max) 3.7 microg x ml(-1), AUC(0-24) 52.4 microg x h x ml(-1)), but still within the limits reported for quinine.",Taste-masked quinine sulphate pellets: bio-availability in adults and steady-state plasma concentrations in children with uncomplicated Plasmodium falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510819/),[h·μg] / [ml],52.4,52222,DB00468,Quinine
,2208897,half-life,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,1 to 4,53513,DB00468,Quinine
,2208897,time to peak concentration,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,7 to 24,53514,DB00468,Quinine
,2208897,time to peak concentration,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,16.7,53515,DB00468,Quinine
,2208897,peak blood concentrations,Mean peak blood concentrations have ranged between 50 and 110 (median 83) ng/ml/mg/kg.,Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],50 and 110,53516,DB00468,Quinine
,2208897,peak blood concentrations,Mean peak blood concentrations have ranged between 50 and 110 (median 83) ng/ml/mg/kg.,Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],83,53517,DB00468,Quinine
,2208897,total apparent volume of distribution (Vd/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [kg],19.2,53518,DB00468,Quinine
,2208897,systemic clearance (CL/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [h·kg],0.022 to 0.073,53519,DB00468,Quinine
,2208897,systemic clearance (CL/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [h·kg],0.026,53520,DB00468,Quinine
,2208897,terminal elimination half-life,"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),d,13.8 to 40.9,53521,DB00468,Quinine
,2208897,terminal elimination half-life,"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),d,20,53522,DB00468,Quinine
,2208897,peak blood concentrations,"In uncomplicated falciparum malaria, peak blood concentrations are 2 to 3 times higher than those in healthy subjects ranging from 112 to 209 (median 144) ng/ml/mg/kg because of contraction in the total apparent volume of distribution.",Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],112 to 209,53523,DB00468,Quinine
,2208897,peak blood concentrations,"In uncomplicated falciparum malaria, peak blood concentrations are 2 to 3 times higher than those in healthy subjects ranging from 112 to 209 (median 144) ng/ml/mg/kg because of contraction in the total apparent volume of distribution.",Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],144,53524,DB00468,Quinine
exceeds,2208897,plasma protein binding,Mefloquine absorption appears to be reduced in severe falciparum malaria; plasma protein binding exceeds 98% in both healthy subjects and patients.,Clinical pharmacokinetics of mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),%,98,53525,DB00468,Quinine
,8600757,peak concentrations,"The im quinine was very rapidly absorbed, reaching high peak concentrations of 16.4 +/- 3.7 mg/L (mean +/- SD) in 1.1 +/- 0.4 hr.",Quinine pharmacokinetics in young children with severe malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600757/),[mg] / [l],16.4,54758,DB00468,Quinine
,8600757,peak levels,Mean peak levels after iv administration were also high (17.5 +/- 2.4 mg/L).,Quinine pharmacokinetics in young children with severe malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600757/),[mg] / [l],17.5,54759,DB00468,Quinine
,21801400,total MCD,The total MCD of tafenoquine required in combination regimens for radical cure was ten-fold lower (1.8 mg/kg versus 18 mg/kg) than for monotherapy.,Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),,1,55856,DB00468,Quinine
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],20-84,55857,DB00468,Quinine
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],"550-1,100",55858,DB00468,Quinine
,1954076,elimination half-life,The mean elimination half-life of quinine in the PMs (10.2 +/- 1.6 (s.d.)h) was similar to that in the EMs (10.9 +/- 1.7 h).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),h,10.2,56523,DB00468,Quinine
,1954076,elimination half-life,The mean elimination half-life of quinine in the PMs (10.2 +/- 1.6 (s.d.)h) was similar to that in the EMs (10.9 +/- 1.7 h).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),h,10.9,56524,DB00468,Quinine
,1954076,oral clearance,The oral clearance of quinine in the PM subjects was 0.092 +/- 0.021 l h-1 kg-1 and was not significantly different (P greater than 0.05) from that observed in the EM subjects (0.073 +/- 0.019 l h-1 kg-1).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),[l] / [h·kg],0.092,56525,DB00468,Quinine
,1954076,oral clearance,The oral clearance of quinine in the PM subjects was 0.092 +/- 0.021 l h-1 kg-1 and was not significantly different (P greater than 0.05) from that observed in the EM subjects (0.073 +/- 0.019 l h-1 kg-1).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),[l] / [h·kg],0.073,56526,DB00468,Quinine
,7546045,t(1/2),"Within the first 15 min after administration, EPR was distributed from the central compartment distinctly faster in compare to the control, when QUI was preadministered (t(1/2) = 6 min for the control group and t(1/2) = 3 min with QUI; -46%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),min,6,56863,DB00468,Quinine
,7546045,t(1/2),"Within the first 15 min after administration, EPR was distributed from the central compartment distinctly faster in compare to the control, when QUI was preadministered (t(1/2) = 6 min for the control group and t(1/2) = 3 min with QUI; -46%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),min,3,56864,DB00468,Quinine
,7546045,Half-life of elimination,Half-life of elimination was 0.5 h for the control group and 8.6 h for the QUI group (-10%).,Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),h,0.5,56865,DB00468,Quinine
,7546045,Half-life of elimination,Half-life of elimination was 0.5 h for the control group and 8.6 h for the QUI group (-10%).,Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),h,8.6,56866,DB00468,Quinine
,7546045,initial serum concentration (co),"The mean initial serum concentration (co) was reduced significantly by QUI from 7359 +/- 506 ng/ml to 4351 +/- 1682 ng/ml (-42%, p < 0.005).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [ml],7359,56867,DB00468,Quinine
,7546045,initial serum concentration (co),"The mean initial serum concentration (co) was reduced significantly by QUI from 7359 +/- 506 ng/ml to 4351 +/- 1682 ng/ml (-42%, p < 0.005).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [ml],4351,56868,DB00468,Quinine
,7546045,serum bioavailability,"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [h·ml],3404,56869,DB00468,Quinine
,7546045,serum bioavailability,"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[h·ml·ng] / [-],2359,56870,DB00468,Quinine
,7546045,AUC(o-24),"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [h·ml],3404,56871,DB00468,Quinine
,7546045,AUC(o-24),"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[h·ml·ng] / [-],2359,56872,DB00468,Quinine
,7546045,total body clearance,"Vd and Vdbeta were increased at about 90% and the mean total body clearance was accelerated from 45.3 to 1487 ml/min, but due to the large standard deviations the calculated difference for these parameters was not statistically significant.",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ml] / [min],45,56873,DB00468,Quinine
,7546045,k(rbc),"In the observed time interval of 24 h, the red blood cell coefficient of distribution k(rbc) of EPR was lower if QUI was coadministered (k(rbc) = 1.25 +/- 0.12 for the control group k(rbc) = 1.15 +/- 0.13 under QUI; p < 0.04).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),,1.25,56874,DB00468,Quinine
,7546045,k(rbc),"In the observed time interval of 24 h, the red blood cell coefficient of distribution k(rbc) of EPR was lower if QUI was coadministered (k(rbc) = 1.25 +/- 0.12 for the control group k(rbc) = 1.15 +/- 0.13 under QUI; p < 0.04).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),,1.15,56875,DB00468,Quinine
,11353629,clearance [CL],A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),[l] / [h·kg],0.05,61280,DB00468,Quinine
,11353629,volume of distribution in the central compartment [V(1)],A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),[l] / [kg],0.65,61281,DB00468,Quinine
,11353629,volume of distribution at steady state,A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),[l] / [kg],1.41,61282,DB00468,Quinine
,11353629,half-life at beta phase,A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),h,19.9,61283,DB00468,Quinine
,23943850,area under the parasite clearance curves,"Circulating late-stage parasites measured as the median area under the parasite clearance curves were 2150 (interquartile range [IQR], 0-28 025) parasites/µL × hour in patients treated with levamisole and 5489 (IQR, 192-25 848) parasites/µL × hour in controls (P = .25).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),[parasites] / [h·μl],2150,64586,DB00468,Quinine
,23943850,area under the parasite clearance curves,"Circulating late-stage parasites measured as the median area under the parasite clearance curves were 2150 (interquartile range [IQR], 0-28 025) parasites/µL × hour in patients treated with levamisole and 5489 (IQR, 192-25 848) parasites/µL × hour in controls (P = .25).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),[parasites] / [h·μl],5489,64587,DB00468,Quinine
,23943850,time to normalization of,"The median time to normalization of plasma lactate (<2 mmol/L) was 24 (IQR, 12-30) hours with levamisole vs 28 (IQR, 12-36) hours without levamisole (P = .15).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),h,24,64588,DB00468,Quinine
,23943850,time to normalization of,"The median time to normalization of plasma lactate (<2 mmol/L) was 24 (IQR, 12-30) hours with levamisole vs 28 (IQR, 12-36) hours without levamisole (P = .15).",Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23943850/),h,28,64589,DB00468,Quinine
,21466937,flow rate,"Both were separated from the internal standard quinine on a reversed phase C18 column, with the mobile phase consisting of a mixture of 1% diethylamine, acetonitrile and methanol (20:55:25, v:v:v) running at a flow rate of 1.0ml/min.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),[ml] / [min],1.0,66829,DB00468,Quinine
,21466937,Retention times,"Retention times of QN, DECQ and CQ were 4.5, 5.7 and 6.4min, respectively.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),min,4.5,66830,DB00468,Quinine
,21466937,Retention times,"Retention times of QN, DECQ and CQ were 4.5, 5.7 and 6.4min, respectively.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),min,5.7,66831,DB00468,Quinine
,21466937,Retention times,"Retention times of QN, DECQ and CQ were 4.5, 5.7 and 6.4min, respectively.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),min,6.4,66832,DB00468,Quinine
,21466937,Limit of quantification (LOQ),Limit of quantification (LOQ) for both CQ and DECQ was accepted as 50ng/ml using 80μl DBS sample and 25ng/ml using 150μl whole blood sample.,HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),[ng] / [ml],50,66833,DB00468,Quinine
,21466937,Limit of quantification (LOQ),Limit of quantification (LOQ) for both CQ and DECQ was accepted as 50ng/ml using 80μl DBS sample and 25ng/ml using 150μl whole blood sample.,HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),[ng] / [ml],25,66834,DB00468,Quinine
,21466937,recoveries,"The mean recoveries for CQ, DECQ and internal standard for both whole blood and DBS were between 74 and 87%.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),%,74 and 87,66835,DB00468,Quinine
,31678424,Km,"Seletalisib was found to be actively transported by rodent and human P-gp in vitro (transfected LLC-PK1 cells; Km of ca. 20 µM), with minimal or no affinity for the other tested transporters.",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),μM,20,67423,DB00468,Quinine
,31678424,"Kp,uu","Restricted brain penetration was also observed in cynomolgus monkeys (single oral dosing at 30 mg kg-1) using brain microdialysis and cerebrospinal fluid sampling (Kp,uu of 0.09 and 0.24, respectively).",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),,0.09,67424,DB00468,Quinine
,31678424,"Kp,uu","Restricted brain penetration was also observed in cynomolgus monkeys (single oral dosing at 30 mg kg-1) using brain microdialysis and cerebrospinal fluid sampling (Kp,uu of 0.09 and 0.24, respectively).",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),,0.24,67425,DB00468,Quinine
,31678424,IC50,"In vitro, CsA inhibited the active transport of seletalisib with an IC50 of 0.13 µM.",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),μM,0.13,67426,DB00468,Quinine
,9657511,maximal plasma quinine concentration,Hearing loss was audiometrically documented in 9 healthy subjects at a mean maximal plasma quinine concentration of only 2 mg/l.,Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657511/),[mg] / [l],2,72522,DB00468,Quinine
,32411255,zeta potential,Microparticles had an average zeta potential of -35.2 mV and an encapsulation efficiency of 94.5%.,Quinine Sulphate Microparticles as Treatment for Leishmaniasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411255/),mv,-,75257,DB00468,Quinine
,32411255,zeta potential,Microparticles had an average zeta potential of -35.2 mV and an encapsulation efficiency of 94.5%.,Quinine Sulphate Microparticles as Treatment for Leishmaniasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411255/),mv,35.2,75258,DB00468,Quinine
,32411255,en,Microparticles had an average zeta potential of -35.2 mV and an encapsulation efficiency of 94.5%.,Quinine Sulphate Microparticles as Treatment for Leishmaniasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411255/),,94,75259,DB00468,Quinine
,12709315,parasite clearance times,"Although parasite clearance times were shorter in the quinine-rifampin-treated patients (mean +/- standard deviation, 70 +/- 21 versus 82 +/- 18 h; P = 0.023), recrudescence rates were five times higher (n = 15 of 23; 65%) than those obtained with quinine alone (n = 3 of 25; 12%), P < 0.001.",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),h,70,81503,DB00468,Quinine
,12709315,parasite clearance times,"Although parasite clearance times were shorter in the quinine-rifampin-treated patients (mean +/- standard deviation, 70 +/- 21 versus 82 +/- 18 h; P = 0.023), recrudescence rates were five times higher (n = 15 of 23; 65%) than those obtained with quinine alone (n = 3 of 25; 12%), P < 0.001.",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),h,82,81504,DB00468,Quinine
,12709315,area under the plasma drug concentration-time curve,"Patients receiving rifampin had significantly greater conversion of quinine to 3-hydroxyquinine and consequently considerably lower concentrations of quinine in their plasma after the second day of treatment (median area under the plasma drug concentration-time curve from day zero to day 7 = 11.7 versus 47.5 micro g/ml. day, P < 0.001).",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),[μg] / [d·ml],11.7,81505,DB00468,Quinine
,12709315,area under the plasma drug concentration-time curve,"Patients receiving rifampin had significantly greater conversion of quinine to 3-hydroxyquinine and consequently considerably lower concentrations of quinine in their plasma after the second day of treatment (median area under the plasma drug concentration-time curve from day zero to day 7 = 11.7 versus 47.5 micro g/ml. day, P < 0.001).",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),[μg] / [d·ml],47.5,81506,DB00468,Quinine
,18036378,limits of detections (LODs),"The limits of detections (LODs) of quinine, using the dynamic DDSME/AP-MALDI/MS in urine and plasma samples were 0.18 and 0.24 microM, respectively.",Quantitative bioanalysis of quinine by atmospheric pressure-matrix assisted laser desorption/ionization mass spectrometry combined with dynamic drop-to-drop solvent microextraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18036378/),μM,0.18,85331,DB00468,Quinine
,18036378,limits of detections (LODs),"The limits of detections (LODs) of quinine, using the dynamic DDSME/AP-MALDI/MS in urine and plasma samples were 0.18 and 0.24 microM, respectively.",Quantitative bioanalysis of quinine by atmospheric pressure-matrix assisted laser desorption/ionization mass spectrometry combined with dynamic drop-to-drop solvent microextraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18036378/),μM,0.24,85332,DB00468,Quinine
,8983859,t1/2z,"There is increased plasma protein binding, predominantly to alpha 1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t1/2z = 11 hours, quinidine t1/2z = 8 hours) are prolonged by 50%.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),h,11,87263,DB00468,Quinine
,8983859,t1/2z,"There is increased plasma protein binding, predominantly to alpha 1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t1/2z = 11 hours, quinidine t1/2z = 8 hours) are prolonged by 50%.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),h,8,87264,DB00468,Quinine
more,8983859,bioavailability,Quinine is well absorbed by mouth or following intramuscular injection even in severe cases of malaria (estimated bioavailability more than 85%).,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),%,85,87265,DB00468,Quinine
more,8983859,total apparent volume of distribution (Vd),"Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),[l] / [kg],100,87266,DB00468,Quinine
,8983859,terminal elimination half-life,"Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),month,1 to 2,87267,DB00468,Quinine
exceeds,8983859,Oral bioavailability,Oral bioavailability exceeds 75%.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),%,75,87268,DB00468,Quinine
,8983859,Vd,Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),[l] / [kg],17 to 34,87269,DB00468,Quinine
,8983859,terminal elimination half-life,Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),weeks,1 to 3,87270,DB00468,Quinine
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,44,91127,DB00468,Quinine
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,30,91128,DB00468,Quinine
,3427208,sensitivity,The sensitivity of the assay is 5 ng ml-1 of plasma or urine for both I and PK.,HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),[ng] / [ml],5,93064,DB00468,Quinine
,3427208,recoveries,"Mean recoveries from plasma for PK, I, and the internal standard (quinine sulfate) were 86.4, 86.8, and 88.5 per cent, respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),%,86.4,93065,DB00468,Quinine
,3427208,recoveries,"Mean recoveries from plasma for PK, I, and the internal standard (quinine sulfate) were 86.4, 86.8, and 88.5 per cent, respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),%,86.8,93066,DB00468,Quinine
,3427208,recoveries,"Mean recoveries from plasma for PK, I, and the internal standard (quinine sulfate) were 86.4, 86.8, and 88.5 per cent, respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),%,88.5,93067,DB00468,Quinine
,3427208,recovery from urine,Mean recovery from urine for I was 82.5%.,HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),%,82.5,93068,DB00468,Quinine
,3427208,tmax,"Peak plasma concentrations for I and PK were obtained in an average time of 2.1 and 2.6 h (tmax), respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),h,2.1,93069,DB00468,Quinine
,3427208,tmax,"Peak plasma concentrations for I and PK were obtained in an average time of 2.1 and 2.6 h (tmax), respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),h,2.6,93070,DB00468,Quinine
,3427208,absorption t1/2,"The mean absorption t1/2 of I was 0.8 h, the mean Vda 878 l and the mean clearance 58 l h-1.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),h,0.8,93071,DB00468,Quinine
,3427208,Vda,"The mean absorption t1/2 of I was 0.8 h, the mean Vda 878 l and the mean clearance 58 l h-1.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),l,878,93072,DB00468,Quinine
,3427208,clearance,"The mean absorption t1/2 of I was 0.8 h, the mean Vda 878 l and the mean clearance 58 l h-1.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),[l] / [h],58,93073,DB00468,Quinine
,3427208,t1/2,"The mean t1/2 for I and PK was 10.4 and 11.9 h, respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),h,10.4,93074,DB00468,Quinine
,3427208,t1/2,"The mean t1/2 for I and PK was 10.4 and 11.9 h, respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),h,11.9,93075,DB00468,Quinine
,3427208,plasma concentrations,"Mean plasma concentrations of I and PK post-dose were 116 ng ml-1 and 43 ng ml-1, respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),[ng] / [ml],116,93076,DB00468,Quinine
,3427208,plasma concentrations,"Mean plasma concentrations of I and PK post-dose were 116 ng ml-1 and 43 ng ml-1, respectively.",HPLC determination of indalpine and its major metabolite in human plasma and a pharmacokinetic application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427208/),[ng] / [ml],43,93077,DB00468,Quinine
,1801332,oral clearance,"The mean oral clearance of quinine was found to be significantly decreased in the elderly (P less than 0.05, 0.062 litre/h/kg vs 0.084 litre/h/kg) as compared to the young.",Pharmacokinetics of quinine in young and elderly subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1801332/),[l] / [h·kg],0.062,95270,DB00468,Quinine
,1801332,oral clearance,"The mean oral clearance of quinine was found to be significantly decreased in the elderly (P less than 0.05, 0.062 litre/h/kg vs 0.084 litre/h/kg) as compared to the young.",Pharmacokinetics of quinine in young and elderly subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1801332/),[l] / [h·kg],0.084,95271,DB00468,Quinine
,1801332,elimination half-life,"This was accompanied by a significant increase in the mean elimination half-life of quinine in the elderly group (18.4 +/- 5.7 [standard deviation] h vs 10.5 +/- 1.6 h, P less than 0.05).",Pharmacokinetics of quinine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1801332/),h,18.4,95272,DB00468,Quinine
,1801332,elimination half-life,"This was accompanied by a significant increase in the mean elimination half-life of quinine in the elderly group (18.4 +/- 5.7 [standard deviation] h vs 10.5 +/- 1.6 h, P less than 0.05).",Pharmacokinetics of quinine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1801332/),h,10.5,95273,DB00468,Quinine
,9080334,flow-rate,"Chromatographic separation consisted of the mobile phase (methanol-water containing 0.005 M octanesulfonic acid, 50:50, v/v) running through the column (Techopak-10 C18) at a flow-rate of 1.6 ml/min.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),[ml] / [min],1.6,95600,DB00468,Quinine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,98.9,95601,DB00468,Quinine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,89,95602,DB00468,Quinine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,94.7,95603,DB00468,Quinine
,9080334,recoveries,"The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN.",Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),%,96,95604,DB00468,Quinine
,9080334,minimum detectable concentrations,The minimum detectable concentrations for PYR and QN in plasma were 3 and 10 ng/ml.,Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),[ng] / [ml],3,95605,DB00468,Quinine
,9080334,minimum detectable concentrations,The minimum detectable concentrations for PYR and QN in plasma were 3 and 10 ng/ml.,Alternative method for determination of pyrimethamine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9080334/),[ng] / [ml],10,95606,DB00468,Quinine
,1771646,volume of distribution,"In the absence of doxycycline, the volume of distribution of quinine (mean +/- SD) was estimated to be 1.32 +/- 0.32 L/kg, and its clearance was 0.125 +/- 0.47 L/h/kg, which was only in partial agreement with previously published data.",Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771646/),[l] / [kg],1.32,98561,DB00468,Quinine
,1771646,clearance,"In the absence of doxycycline, the volume of distribution of quinine (mean +/- SD) was estimated to be 1.32 +/- 0.32 L/kg, and its clearance was 0.125 +/- 0.47 L/h/kg, which was only in partial agreement with previously published data.",Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771646/),[l] / [h·kg],0.125,98562,DB00468,Quinine
,26032168,plasma Tmax,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼2,98635,DB00468,Quinine
,26032168,t1/2,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼10,98636,DB00468,Quinine
,26032168,elimination t1/2,"During washout, quinine urinary concentrations steadily declined (elimination t1/2 ∼16 hours), with a 94% decrease observed 72 hours postdose.",Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼16,98637,DB00468,Quinine
,1880724,systemic clearance,"After separate dosage, systemic clearance of quinine tended to be greater than that of quinidine (714 +/- 299 versus 422 +/- 146 mL/min, p = 0.08).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],714,99435,DB00468,Quinine
,1880724,systemic clearance,"After separate dosage, systemic clearance of quinine tended to be greater than that of quinidine (714 +/- 299 versus 422 +/- 146 mL/min, p = 0.08).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],422,99436,DB00468,Quinine
,1880724,Cf:Cm ratios,"After separate dosage, fetal total concentrations (Cf) of quinine and quinidine were substantially lower than maternal total concentrations, as reflected in Cf:Cm ratios of 0.15 +/- 0.06 versus 0.10 +/- 0.08, respectively.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.15,99437,DB00468,Quinine
,1880724,Cf:Cm ratios,"After separate dosage, fetal total concentrations (Cf) of quinine and quinidine were substantially lower than maternal total concentrations, as reflected in Cf:Cm ratios of 0.15 +/- 0.06 versus 0.10 +/- 0.08, respectively.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.10,99438,DB00468,Quinine
,1880724,Cfu/Cmu,"Similarly, fetal unbound concentrations (Cfu) were substantially lower than maternal unbound concentrations (Cmu; Cfu/Cmu = 0.46 +/- 0.09 for quinine and 0.23 +/- 0.09 for quinidine).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.46,99439,DB00468,Quinine
,1880724,Cfu/Cmu,"Similarly, fetal unbound concentrations (Cfu) were substantially lower than maternal unbound concentrations (Cmu; Cfu/Cmu = 0.46 +/- 0.09 for quinine and 0.23 +/- 0.09 for quinidine).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.23,99440,DB00468,Quinine
,1880724,renal clearances,"Fetal renal clearances of quinine and quinidine were similar (0.34 +/- 0.24 mL/min versus 0.38 +/- 0.24 mL/min) and less than that of endogenous creatinine, indicating the absence of net renal tubular secretion.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],0.34,99441,DB00468,Quinine
,1880724,renal clearances,"Fetal renal clearances of quinine and quinidine were similar (0.34 +/- 0.24 mL/min versus 0.38 +/- 0.24 mL/min) and less than that of endogenous creatinine, indicating the absence of net renal tubular secretion.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],0.38,99442,DB00468,Quinine
,1880724,Cf:Cm,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.48,99443,DB00468,Quinine
,1880724,Cf:Cm,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.31,99444,DB00468,Quinine
,1880724,Cfu:Cmu,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.73,99445,DB00468,Quinine
,1880724,Cfu:Cmu,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.52,99446,DB00468,Quinine
,23183442,elimination clearance,"Population pharmacokinetic parameter estimates (and percent relative standard errors [%RSE]) of elimination clearance, central volume of distribution, and duration of zero-order absorption were 0.977 liters/h (6.50%), 16.7 liters (6.39%), and 1.42 h (21.5%), respectively, for a typical patient weighing 11 kg.",Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183442/),[l] / [h],0.977,104523,DB00468,Quinine
,23183442,central volume of distribution,"Population pharmacokinetic parameter estimates (and percent relative standard errors [%RSE]) of elimination clearance, central volume of distribution, and duration of zero-order absorption were 0.977 liters/h (6.50%), 16.7 liters (6.39%), and 1.42 h (21.5%), respectively, for a typical patient weighing 11 kg.",Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183442/),l,16.7,104524,DB00468,Quinine
,23183442,duration of zero-order absorption,"Population pharmacokinetic parameter estimates (and percent relative standard errors [%RSE]) of elimination clearance, central volume of distribution, and duration of zero-order absorption were 0.977 liters/h (6.50%), 16.7 liters (6.39%), and 1.42 h (21.5%), respectively, for a typical patient weighing 11 kg.",Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183442/),h,1.42,104525,DB00468,Quinine
,9618735,parasite,"An oral dose of 10 mg/kg quinine dihydrochloride administered 8-hourly for 7 days gave parasite and fever clearance times of 36.0 +/- 16.6 h and 18.0 +/- 6.4 h, respectively.",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),h,36.0,110901,DB00468,Quinine
,9618735,fever clearance times,"An oral dose of 10 mg/kg quinine dihydrochloride administered 8-hourly for 7 days gave parasite and fever clearance times of 36.0 +/- 16.6 h and 18.0 +/- 6.4 h, respectively.",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),h,18.0,110902,DB00468,Quinine
,9618735,AUC(0-12),In acute malaria plasma quinine levels were more than two-fold higher than in convalescence; the mean AUC(0-12) in malaria was 37.9 +/- 14.7 micrograms.h/ml compared to 17.9 +/- 8.5 micrograms.h/ml in convalescence.,Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[h·μg] / [ml],37.9,110903,DB00468,Quinine
,9618735,AUC(0-12),In acute malaria plasma quinine levels were more than two-fold higher than in convalescence; the mean AUC(0-12) in malaria was 37.9 +/- 14.7 micrograms.h/ml compared to 17.9 +/- 8.5 micrograms.h/ml in convalescence.,Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[h·μg] / [ml],17.9,110904,DB00468,Quinine
,9618735,apparent oral clearance (CL/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[ml] / [kg·min],1.9,110905,DB00468,Quinine
,9618735,apparent oral clearance (CL/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[ml] / [kg·min],4.5,110906,DB00468,Quinine
,9618735,volume of distribution (Vd/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[l] / [kg],1.8,110907,DB00468,Quinine
,9618735,volume of distribution (Vd/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[l] / [kg],4.2,110908,DB00468,Quinine
,33526485,peak concentrations,"After rectal artesunate, artesunate and dihydroartemisinin showed large interindividual variability (peak concentrations of dihydroartemisinin ranged from 5.63 to 8,090 nM).",Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526485/),nM,"5.63 to 8,090",114124,DB00468,Quinine
,33526485,time above IC50,"The median (interquartile range [IQR]) time above IC50 and IC90 was 5.68 h (2.90 to 6.08) and 2.74 h (1.52 to 3.75), respectively.",Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526485/),h,5.68,114125,DB00468,Quinine
,33526485,IC90,"The median (interquartile range [IQR]) time above IC50 and IC90 was 5.68 h (2.90 to 6.08) and 2.74 h (1.52 to 3.75), respectively.",Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526485/),h,2.74,114126,DB00468,Quinine
,33526485,absolute rectal bioavailability,The absolute rectal bioavailability (IQR) was 25.6% (11.7 to 54.5) for artesunate and 19.8% (10.3 to 35.3) for dihydroartemisinin.,Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526485/),%,25.6,114127,DB00468,Quinine
,33526485,absolute rectal bioavailability,The absolute rectal bioavailability (IQR) was 25.6% (11.7 to 54.5) for artesunate and 19.8% (10.3 to 35.3) for dihydroartemisinin.,Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526485/),%,19.8,114128,DB00468,Quinine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],41.2,114191,DB00468,Quinine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],135,114192,DB00468,Quinine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],18.2,114193,DB00468,Quinine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],25.2,114194,DB00468,Quinine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],9.6,118977,DB00468,Quinine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],3.1,118978,DB00468,Quinine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],9.8,118979,DB00468,Quinine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],3.5,118980,DB00468,Quinine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,1198,118981,DB00468,Quinine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,466,118982,DB00468,Quinine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,1352,118983,DB00468,Quinine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,317,118984,DB00468,Quinine
,7746027,absolute bioavailability,The absolute bioavailability of theophylline and quinine from the two formulations Limptar and Limptar N was nearly complete (90% on the average).,Study on the absolute bioavailability of quinine and theophylline from tablets after single dose oral administration as compared to intravenous infusion in healthy male non-smoking volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7746027/),%,90,120106,DB00468,Quinine
,3524743,Fever,Fever and parasite clearance times (mean (SD) 60 (23) h and 53 (22) h respectively) were comparable with those obtained with intravenous quinine.,Intramuscular loading dose of quinine for falciparum malaria: pharmacokinetics and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524743/),h,60,120593,DB00468,Quinine
,3524743,parasite clearance times,Fever and parasite clearance times (mean (SD) 60 (23) h and 53 (22) h respectively) were comparable with those obtained with intravenous quinine.,Intramuscular loading dose of quinine for falciparum malaria: pharmacokinetics and toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524743/),h,53,120594,DB00468,Quinine
,3524743,peak plasma quinine concentration,The mean peak plasma quinine concentration of 11.0 mg/l (34.4 mu mol/l) [corrected] was reached a median of five hours after administration of the loading dose.,Intramuscular loading dose of quinine for falciparum malaria: pharmacokinetics and toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524743/),[mg] / [l],11.0,120595,DB00468,Quinine
,20230885,steady state quinine plasma concentration,"The fast decline in parasitemia (28.6%/24h), the reduction rate of fever (all children were apyretic after 72 h) and the steady state quinine plasma concentration (5.7-15.8 microg/ml) proved the efficacy of the quinine pamoate tablets against P. falciparum.",Taste-masked quinine pamoate tablets for treatment of children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230885/),[μg] / [ml],5.7-15.8,121061,DB00468,Quinine
,20054526,metabolic ratio,"Patients that achieved complete molecular response showed significantly (Mann-Whitney U-test, p=0.013) higher in vivo CYP3A activity (median quinine metabolic ratio = 10.1) than patients achieving partial molecular response (median = 15.9).",CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20054526/),,10.1,122997,DB00468,Quinine
above,22186076,residual concentrations,The efficacy of quinine has been proved for residual concentrations above 5 mg/L (15 μmol/L) throughout the duration of treatment.,[Therapeutic drug monitoring of quinine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186076/),[mg] / [l],5,124427,DB00468,Quinine
,22186076,residual concentrations,The efficacy of quinine has been proved for residual concentrations above 5 mg/L (15 μmol/L) throughout the duration of treatment.,[Therapeutic drug monitoring of quinine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186076/),[μM] / [l],15,124428,DB00468,Quinine
,22186076,trough concentration,The 2007 consensus conference of the French Language Infectious Diseases Society calls for daily monitoring of plasma concentrations during the first 3 days of treatment targeting a trough concentration between 10 and 12 mg/L (30-36 μmol/L).,[Therapeutic drug monitoring of quinine]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186076/),[mg] / [l],10 and 12,124429,DB00468,Quinine
,22186076,trough concentration,The 2007 consensus conference of the French Language Infectious Diseases Society calls for daily monitoring of plasma concentrations during the first 3 days of treatment targeting a trough concentration between 10 and 12 mg/L (30-36 μmol/L).,[Therapeutic drug monitoring of quinine]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186076/),[μM] / [l],30-36,124430,DB00468,Quinine
,12959277,parasite clearance time,"Halofantrine cleared parasitaemia rapidly in all but one patient, with a mean (s.d.) parasite clearance time of 71 (29) h.","Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),h,71,129134,DB00468,Quinine
,12959277,V1,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),[l] / [kg],0.36,129135,DB00468,Quinine
,12959277,CL,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),[l] / [h·kg],0.355,129136,DB00468,Quinine
,12959277,t1/2alpha,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),h,0.19,129137,DB00468,Quinine
,12959277,t1/2beta,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),h,14.4,129138,DB00468,Quinine
,2189012,Plasma,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],8.7,131268,DB00468,Quinine
,2189012,Plasma,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],11.0,131269,DB00468,Quinine
,2189012,concentrations,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],8.7,131270,DB00468,Quinine
,2189012,concentrations,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],11.0,131271,DB00468,Quinine
,23917320,concentrations,"Median day 7 lumefantrine concentrations were 488 (range, 30.7 to 3,550) ng/ml in pregnant women compared to 720 (339 to 2,150) ng/ml in nonpregnant women (P = 0.128).","Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23917320/),[ng] / [ml],488,133608,DB00468,Quinine
,23917320,concentrations,"Median day 7 lumefantrine concentrations were 488 (range, 30.7 to 3,550) ng/ml in pregnant women compared to 720 (339 to 2,150) ng/ml in nonpregnant women (P = 0.128).","Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23917320/),[ng] / [ml],720,133609,DB00468,Quinine
,31871506,absorption rate constant,"The absorption rate constant, and volume of distribution and clearance were 1.72 h-1, 86.8 to 157.4 L, and 6.6 to 9.6 L/h, respectively.",Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871506/),1/[h],1.72,133786,DB00468,Quinine
,31871506,volume of distribution,"The absorption rate constant, and volume of distribution and clearance were 1.72 h-1, 86.8 to 157.4 L, and 6.6 to 9.6 L/h, respectively.",Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871506/),l,86.8 to 157.4,133787,DB00468,Quinine
,31871506,clearance,"The absorption rate constant, and volume of distribution and clearance were 1.72 h-1, 86.8 to 157.4 L, and 6.6 to 9.6 L/h, respectively.",Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871506/),[l] / [h],6.6 to 9.6,133788,DB00468,Quinine
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,82,134636,DB00468,Quinine
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,81,134637,DB00468,Quinine
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,93,134638,DB00468,Quinine
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,99,134639,DB00468,Quinine
,8116811,side effects,"The side effects score was lower (2 versus 11; P < 0.001), there were less days on which side effects occurred (2.0 days versus 5.5 days; P < 0.001), and fewer patients had adverse effects on every treatment day (4% versus 42%; P < 0.01).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),,2,134640,DB00468,Quinine
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB00468,Quinine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB00468,Quinine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB00468,Quinine
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB00468,Quinine
,3887162,Times,"Times required for parasite clearance and elimination of fever (49.4 +/- 17.8 and 69.5 +/- 18.7 hours, respectively) were comparable to those in earlier studies with a loading dose of quinine.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,49.4,136289,DB00468,Quinine
,3887162,Times,"Times required for parasite clearance and elimination of fever (49.4 +/- 17.8 and 69.5 +/- 18.7 hours, respectively) were comparable to those in earlier studies with a loading dose of quinine.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,69.5,136290,DB00468,Quinine
,3887162,elimination half-life,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,12.8,136291,DB00468,Quinine
,3887162,volume of distribution,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[l] / [kg],1.68,136292,DB00468,Quinine
,3887162,total clearance,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[ml] / [kg·min],1.75,136293,DB00468,Quinine
,3887162,urinary clearance,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[ml] / [kg·min],0.62,136294,DB00468,Quinine
,10750517,parasite clearance time (PCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),d,two,138310,DB00468,Quinine
,10750517,fever clearance time (FCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),h,48,138311,DB00468,Quinine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],134,139399,DB00468,Quinine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],87,139400,DB00468,Quinine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],95,139401,DB00468,Quinine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],55,139402,DB00468,Quinine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],155,139403,DB00468,Quinine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],110,139404,DB00468,Quinine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],177,139405,DB00468,Quinine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],185,139406,DB00468,Quinine
,27526669,extraction recovery,The extraction recovery was between 87 and 93% for both compounds with no matrix effects on the analysis.,Quantification of mesembrine and mesembrenone in mouse plasma using UHPLC-QToF-MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526669/),%,87 and 93,140516,DB00468,Quinine
,7604754,absolute bioavailability,The absolute bioavailability was 64.5 and 64.3% for the quinine sulphate capsule and the quinine dihydrochloride plain tablet respectively.,Bioavailability of sulphate and dihydrochloride salts of quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604754/),%,64.5,143628,DB00468,Quinine
,7604754,absolute bioavailability,The absolute bioavailability was 64.5 and 64.3% for the quinine sulphate capsule and the quinine dihydrochloride plain tablet respectively.,Bioavailability of sulphate and dihydrochloride salts of quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604754/),%,64.3,143629,DB00468,Quinine
,24282507,IC50,"It had IC50 values of 0.37 and 0.55 µg/mL, against 3D7 and Dd2 respectively.","New antimalarial hits from Dacryodes edulis (Burseraceae)--part I: isolation, in vitro activity, in silico ""drug-likeness"" and pharmacokinetic profiles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24282507/),[μg] / [ml],0.37,147197,DB00468,Quinine
,24282507,IC50,"It had IC50 values of 0.37 and 0.55 µg/mL, against 3D7 and Dd2 respectively.","New antimalarial hits from Dacryodes edulis (Burseraceae)--part I: isolation, in vitro activity, in silico ""drug-likeness"" and pharmacokinetic profiles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24282507/),[μg] / [ml],0.55,147198,DB00468,Quinine
,6751085,Cl,"Quinine total clearances (Cl) and total apparent volumes of distribution (Vd) were significantly lower than in uncomplicated malaria (Cl, 0.92 +/- 0.42 compared with 1.35 +/- 0.6 ml/min/kg, p = 0.03; Vd, 1.18 +/- 0.37 compared with 1.67 +/- 0.34 liter/kg, p = 0.0013).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[ml] / [kg·min],0.92,147673,DB00468,Quinine
,6751085,Cl,"Quinine total clearances (Cl) and total apparent volumes of distribution (Vd) were significantly lower than in uncomplicated malaria (Cl, 0.92 +/- 0.42 compared with 1.35 +/- 0.6 ml/min/kg, p = 0.03; Vd, 1.18 +/- 0.37 compared with 1.67 +/- 0.34 liter/kg, p = 0.0013).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[ml] / [kg·min],1.35,147674,DB00468,Quinine
,6751085,Vd,"Quinine total clearances (Cl) and total apparent volumes of distribution (Vd) were significantly lower than in uncomplicated malaria (Cl, 0.92 +/- 0.42 compared with 1.35 +/- 0.6 ml/min/kg, p = 0.03; Vd, 1.18 +/- 0.37 compared with 1.67 +/- 0.34 liter/kg, p = 0.0013).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[l] / [kg],1.18,147675,DB00468,Quinine
,6751085,Vd,"Quinine total clearances (Cl) and total apparent volumes of distribution (Vd) were significantly lower than in uncomplicated malaria (Cl, 0.92 +/- 0.42 compared with 1.35 +/- 0.6 ml/min/kg, p = 0.03; Vd, 1.18 +/- 0.37 compared with 1.67 +/- 0.34 liter/kg, p = 0.0013).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[l] / [kg],1.67,147676,DB00468,Quinine
,6751085,t/2,"There was no significant difference between the two groups in elimination half-times (t/2) or renal clearances (Cu) (t/2, 18.2 +/- 9.7 compared with 16 +/- 7.0 hours; Cu, 0.21 +/- 0.16 compared with 0.21 +/- 0.08 ml/min/kg).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),h,18.2,147677,DB00468,Quinine
,6751085,t/2,"There was no significant difference between the two groups in elimination half-times (t/2) or renal clearances (Cu) (t/2, 18.2 +/- 9.7 compared with 16 +/- 7.0 hours; Cu, 0.21 +/- 0.16 compared with 0.21 +/- 0.08 ml/min/kg).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),h,16,147678,DB00468,Quinine
,6751085,Cu,"There was no significant difference between the two groups in elimination half-times (t/2) or renal clearances (Cu) (t/2, 18.2 +/- 9.7 compared with 16 +/- 7.0 hours; Cu, 0.21 +/- 0.16 compared with 0.21 +/- 0.08 ml/min/kg).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[ml] / [kg·min],0.21,147679,DB00468,Quinine
,6751085,Cu,"There was no significant difference between the two groups in elimination half-times (t/2) or renal clearances (Cu) (t/2, 18.2 +/- 9.7 compared with 16 +/- 7.0 hours; Cu, 0.21 +/- 0.16 compared with 0.21 +/- 0.08 ml/min/kg).",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[ml] / [kg·min],0.21,147680,DB00468,Quinine
,6751085,Cl,"In nine patients studied following recovery, Cl (3.09 +/- 1.18 ml/min), Vd (2.74 +/- 0.47 liter/kg), and Cu (0.53 +/- 0.22 ml/min/kg) were significantly greater (p less than or equal to 0.0004), and t/2 was significantly shorter (11.1 +/- 4.1 hours, p = 0.006) than during the acute illness.",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[ml] / [min],3.09,147681,DB00468,Quinine
,6751085,Vd,"In nine patients studied following recovery, Cl (3.09 +/- 1.18 ml/min), Vd (2.74 +/- 0.47 liter/kg), and Cu (0.53 +/- 0.22 ml/min/kg) were significantly greater (p less than or equal to 0.0004), and t/2 was significantly shorter (11.1 +/- 4.1 hours, p = 0.006) than during the acute illness.",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[l] / [kg],2.74,147682,DB00468,Quinine
,6751085,Cu,"In nine patients studied following recovery, Cl (3.09 +/- 1.18 ml/min), Vd (2.74 +/- 0.47 liter/kg), and Cu (0.53 +/- 0.22 ml/min/kg) were significantly greater (p less than or equal to 0.0004), and t/2 was significantly shorter (11.1 +/- 4.1 hours, p = 0.006) than during the acute illness.",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),[ml] / [kg·min],0.53,147683,DB00468,Quinine
,6751085,t/2,"In nine patients studied following recovery, Cl (3.09 +/- 1.18 ml/min), Vd (2.74 +/- 0.47 liter/kg), and Cu (0.53 +/- 0.22 ml/min/kg) were significantly greater (p less than or equal to 0.0004), and t/2 was significantly shorter (11.1 +/- 4.1 hours, p = 0.006) than during the acute illness.",Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6751085/),h,11.1,147684,DB00468,Quinine
,12492607,apparent volume of distribution,"Accordingly, the free fraction of quinine was decreased (0.024 vs 0.063 [mean difference 0.0380; 95% CI 0.0221, 0.0539]) and the apparent volume of distribution tended to decrease (0.95 l kg-1 vs 1.43 l kg-1 [mean difference 0.480; 95% CI 0.193, 1.154]).",Quinine pharmacokinetics in chronic haemodialysis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[l] / [kg],0.95,149473,DB00468,Quinine
,12492607,apparent volume of distribution,"Accordingly, the free fraction of quinine was decreased (0.024 vs 0.063 [mean difference 0.0380; 95% CI 0.0221, 0.0539]) and the apparent volume of distribution tended to decrease (0.95 l kg-1 vs 1.43 l kg-1 [mean difference 0.480; 95% CI 0.193, 1.154]).",Quinine pharmacokinetics in chronic haemodialysis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[l] / [kg],1.43,149474,DB00468,Quinine
,12492607,clearance,"The clearance of free (unbound) quinine was increased in haemodialysis patients compared with controls (67.9 ml min-1 kg-1 vs 41.1 ml min-1 kg-1 [mean difference -26.8; 95% CI, -56.994, 3.469]), and the area under the curve (AUC) of the two main metabolites, 3-hydroxyquinine and 10,11-dihydroxydihydroquinine were increased.",Quinine pharmacokinetics in chronic haemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[ml] / [kg·min],67.9,149475,DB00468,Quinine
,12492607,clearance,"The clearance of free (unbound) quinine was increased in haemodialysis patients compared with controls (67.9 ml min-1 kg-1 vs 41.1 ml min-1 kg-1 [mean difference -26.8; 95% CI, -56.994, 3.469]), and the area under the curve (AUC) of the two main metabolites, 3-hydroxyquinine and 10,11-dihydroxydihydroquinine were increased.",Quinine pharmacokinetics in chronic haemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[ml] / [kg·min],41.1,149476,DB00468,Quinine
,8105056,Clearance,"Clearance of antipyrine in the capsaicin-pretreated rats was significantly lower than that observed in the control rats (0.241 +/- 0.029 vs 0.344 +/- 0.034 L h-1 kg-1, P < 0.05).","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),[l] / [h·kg],0.241,151535,DB00468,Quinine
,8105056,Clearance,"Clearance of antipyrine in the capsaicin-pretreated rats was significantly lower than that observed in the control rats (0.241 +/- 0.029 vs 0.344 +/- 0.034 L h-1 kg-1, P < 0.05).","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),[l] / [h·kg],0.344,151536,DB00468,Quinine
,8105056,elimination half-life,"This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2.06 +/- 0.30 vs 1.61 +/- 0.27 h), as the volume of distribution was not significantly changed.","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),h,2.06,151537,DB00468,Quinine
,8105056,elimination half-life,"This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2.06 +/- 0.30 vs 1.61 +/- 0.27 h), as the volume of distribution was not significantly changed.","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),h,1.61,151538,DB00468,Quinine
,2706192,admission plasma concentration,In five symptomatic patients with acute quinine poisoning the mean admission plasma concentration was 11.1 mg l-1.,Treatment of quinine overdosage with repeated oral charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706192/),[mg] / [l],11.1,152151,DB00468,Quinine
,2706192,half-life,"After treatment with repeated oral charcoal 50 g 4 hourly, plasma quinine concentrations fell rapidly with a mean half-life of 8.1 +/- 1.1 h (s.d.) compared with more than 24 h in a previous report in similarly poisoned patients.",Treatment of quinine overdosage with repeated oral charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706192/),h,8.1,152152,DB00468,Quinine
more,2706192,half-life,"After treatment with repeated oral charcoal 50 g 4 hourly, plasma quinine concentrations fell rapidly with a mean half-life of 8.1 +/- 1.1 h (s.d.) compared with more than 24 h in a previous report in similarly poisoned patients.",Treatment of quinine overdosage with repeated oral charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706192/),h,24,152153,DB00468,Quinine
,8756050,peak concentrations,Quinine was rapidly absorbed reaching a mean peak concentrations of 2.9 (sd 0.5) and 4.5 (1.3) mg L-1 respectively in a median time of 3.0 (range 2.0-4.0) and 1.5 (range 0.5 4.0) h respectively after oral and intramuscular administration.,Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[mg] / [l],2.9,153439,DB00468,Quinine
,8756050,peak concentrations,Quinine was rapidly absorbed reaching a mean peak concentrations of 2.9 (sd 0.5) and 4.5 (1.3) mg L-1 respectively in a median time of 3.0 (range 2.0-4.0) and 1.5 (range 0.5 4.0) h respectively after oral and intramuscular administration.,Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[mg] / [l],4.5,153440,DB00468,Quinine
,8756050,time,Quinine was rapidly absorbed reaching a mean peak concentrations of 2.9 (sd 0.5) and 4.5 (1.3) mg L-1 respectively in a median time of 3.0 (range 2.0-4.0) and 1.5 (range 0.5 4.0) h respectively after oral and intramuscular administration.,Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),h,3.0,153441,DB00468,Quinine
,8756050,time,Quinine was rapidly absorbed reaching a mean peak concentrations of 2.9 (sd 0.5) and 4.5 (1.3) mg L-1 respectively in a median time of 3.0 (range 2.0-4.0) and 1.5 (range 0.5 4.0) h respectively after oral and intramuscular administration.,Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),h,1.5,153442,DB00468,Quinine
,8756050,Cmax,"The peak concentration (Cmax) was significantly higher after intramuscular than after oral administration [Cmax = 4.5 (1.3) versus 2.9 (0.5) mg L-1, p < 0.01].",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[mg] / [l],4.5,153443,DB00468,Quinine
,8756050,Cmax,"The peak concentration (Cmax) was significantly higher after intramuscular than after oral administration [Cmax = 4.5 (1.3) versus 2.9 (0.5) mg L-1, p < 0.01].",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[mg] / [l],2.9,153444,DB00468,Quinine
,8756050,half-life [t1/2z,"The mean half-life [t1/2z = 11.7 (2.9) versus 10.7 (3.5) h, P > 0.2] respectively, volume of distribution (Vz = 2.5 (0.7) versus 2.2 (0.99) L Kg-1, P > 0.2) respectively and estimated plasma clearance [CLp = 0.15 (0.04) versus 0.15 (0.09) L h-1 Kg-1, P > 0.2] respectively were not significantly different after oral and intramuscular administration.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),h,11.7,153445,DB00468,Quinine
,8756050,half-life [t1/2z,"The mean half-life [t1/2z = 11.7 (2.9) versus 10.7 (3.5) h, P > 0.2] respectively, volume of distribution (Vz = 2.5 (0.7) versus 2.2 (0.99) L Kg-1, P > 0.2) respectively and estimated plasma clearance [CLp = 0.15 (0.04) versus 0.15 (0.09) L h-1 Kg-1, P > 0.2] respectively were not significantly different after oral and intramuscular administration.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),h,10.7,153446,DB00468,Quinine
,8756050,volume of distribution (Vz,"The mean half-life [t1/2z = 11.7 (2.9) versus 10.7 (3.5) h, P > 0.2] respectively, volume of distribution (Vz = 2.5 (0.7) versus 2.2 (0.99) L Kg-1, P > 0.2) respectively and estimated plasma clearance [CLp = 0.15 (0.04) versus 0.15 (0.09) L h-1 Kg-1, P > 0.2] respectively were not significantly different after oral and intramuscular administration.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[l] / [kg],2.5,153447,DB00468,Quinine
,8756050,volume of distribution (Vz,"The mean half-life [t1/2z = 11.7 (2.9) versus 10.7 (3.5) h, P > 0.2] respectively, volume of distribution (Vz = 2.5 (0.7) versus 2.2 (0.99) L Kg-1, P > 0.2) respectively and estimated plasma clearance [CLp = 0.15 (0.04) versus 0.15 (0.09) L h-1 Kg-1, P > 0.2] respectively were not significantly different after oral and intramuscular administration.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[l] / [kg],2.2,153448,DB00468,Quinine
,8756050,plasma clearance [CLp,"The mean half-life [t1/2z = 11.7 (2.9) versus 10.7 (3.5) h, P > 0.2] respectively, volume of distribution (Vz = 2.5 (0.7) versus 2.2 (0.99) L Kg-1, P > 0.2) respectively and estimated plasma clearance [CLp = 0.15 (0.04) versus 0.15 (0.09) L h-1 Kg-1, P > 0.2] respectively were not significantly different after oral and intramuscular administration.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[l] / [h·kg],0.15,153449,DB00468,Quinine
,8756050,plasma clearance [CLp,"The mean half-life [t1/2z = 11.7 (2.9) versus 10.7 (3.5) h, P > 0.2] respectively, volume of distribution (Vz = 2.5 (0.7) versus 2.2 (0.99) L Kg-1, P > 0.2) respectively and estimated plasma clearance [CLp = 0.15 (0.04) versus 0.15 (0.09) L h-1 Kg-1, P > 0.2] respectively were not significantly different after oral and intramuscular administration.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),[l] / [h·kg],0.15,153450,DB00468,Quinine
,8756050,AUCo-oo,"The mean AUCo-oo was higher after intramuscular than after oral administration [71.8 (29.4) versus 54.9 (19.2) mg.h.L, P > 0.1] respectively but this was not significant.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),h·l·mg,71.8,153451,DB00468,Quinine
,8756050,AUCo-oo,"The mean AUCo-oo was higher after intramuscular than after oral administration [71.8 (29.4) versus 54.9 (19.2) mg.h.L, P > 0.1] respectively but this was not significant.",Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756050/),h·l·mg,54.9,153452,DB00468,Quinine
,12610739,C(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),[μg] / [ml],6.9,157489,DB00468,Quinine
,12610739,C(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),[μg] / [ml],5.2,157490,DB00468,Quinine
,12610739,C(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),[μg] / [ml],3.5,157491,DB00468,Quinine
,12610739,C(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),[μg] / [ml],3.1,157492,DB00468,Quinine
,12610739,t(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),h,3.6,157493,DB00468,Quinine
,12610739,t(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),h,4.2,157494,DB00468,Quinine
,12610739,t(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),h,4.0,157495,DB00468,Quinine
,12610739,t(max),"Quinine C(max) values were higher after intravenous infusion of the hydrochloride salt and Cinchona alkaloid mixture (6.9+/-1.9 micro g/ml and 5.2+/-1.3 micro g/ml) than after intrarectal administration (3.5+/-1.4 micro g/ml and 3.1+/-1.6 micro g/ml), but t(max) values were similar (3.6+/-1.5, 4.2+/-1.0, 4.0+/-1.9, and 4.7+/-2.0 h, respectively).",Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),h,4.7,157496,DB00468,Quinine
,12610739,relative bioavailabilities,Intrarectal relative bioavailabilities of hydrochloride salt solution (57%) and Cinchona alkaloid mixture (62%) were similar.,Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),%,57,157497,DB00468,Quinine
,12610739,relative bioavailabilities,Intrarectal relative bioavailabilities of hydrochloride salt solution (57%) and Cinchona alkaloid mixture (62%) were similar.,Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610739/),%,62,157498,DB00468,Quinine
,7826821,absorption lag-time,"3. Absorption and elimination half-times, volume of distribution and oral clearance of quinine were comparable in the two groups (P > 0.2) and there was a mean absorption lag-time of approximately 1 h.",The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826821/),h,1,158463,DB00468,Quinine
,3527243,"total apparent volume of distribution, V","These data were therefore fitted to a one compartment model: total apparent volume of distribution, V, 0.96 +/- 0.27 l kg-1 (+/- s.d.), elimination half-time (t1/2,z), 11.3 +/- 4.3 h, total clearance, 1.22 +/- 0.77 ml min-1 kg-1.",Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),[l] / [kg],0.96,159891,DB00468,Quinine
,3527243,"elimination half-time (t1/2,z)","These data were therefore fitted to a one compartment model: total apparent volume of distribution, V, 0.96 +/- 0.27 l kg-1 (+/- s.d.), elimination half-time (t1/2,z), 11.3 +/- 4.3 h, total clearance, 1.22 +/- 0.77 ml min-1 kg-1.",Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),h,11.3,159892,DB00468,Quinine
,3527243,total clearance,"These data were therefore fitted to a one compartment model: total apparent volume of distribution, V, 0.96 +/- 0.27 l kg-1 (+/- s.d.), elimination half-time (t1/2,z), 11.3 +/- 4.3 h, total clearance, 1.22 +/- 0.77 ml min-1 kg-1.",Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),[ml] / [kg·min],1.22,159893,DB00468,Quinine
,3527243,concentrations,Breast milk quinine concentrations and milk to plasma ratios were 0.5-3.6 mg l-1 (mean 2.6) and 0.11-0.53 (mean 0.31) in twenty-five women who were breast-feeding and had taken oral quinine sulphate for 1-10 days (mean 4.0).,Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),[mg] / [l],0.5-3.6,159894,DB00468,Quinine
,3527243,concentrations,Breast milk quinine concentrations and milk to plasma ratios were 0.5-3.6 mg l-1 (mean 2.6) and 0.11-0.53 (mean 0.31) in twenty-five women who were breast-feeding and had taken oral quinine sulphate for 1-10 days (mean 4.0).,Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),[mg] / [l],2.6,159895,DB00468,Quinine
,3527243,milk to plasma ratios,Breast milk quinine concentrations and milk to plasma ratios were 0.5-3.6 mg l-1 (mean 2.6) and 0.11-0.53 (mean 0.31) in twenty-five women who were breast-feeding and had taken oral quinine sulphate for 1-10 days (mean 4.0).,Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),[mg] / [l],2.6,159896,DB00468,Quinine
,3527243,milk to plasma ratios,Breast milk quinine concentrations and milk to plasma ratios were 0.5-3.6 mg l-1 (mean 2.6) and 0.11-0.53 (mean 0.31) in twenty-five women who were breast-feeding and had taken oral quinine sulphate for 1-10 days (mean 4.0).,Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),,0.11-0.53,159897,DB00468,Quinine
,3527243,milk to plasma ratios,Breast milk quinine concentrations and milk to plasma ratios were 0.5-3.6 mg l-1 (mean 2.6) and 0.11-0.53 (mean 0.31) in twenty-five women who were breast-feeding and had taken oral quinine sulphate for 1-10 days (mean 4.0).,Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3527243/),,0.31,159898,DB00468,Quinine
,10492795,clearance,"The estimated median (range) quinine clearance was 0.83 mL/kg/min (0.58-1.16), and 3OHQn clearance/fraction of quinine converted was 3.40 mL/kg/min (2.58-4.47).",Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492795/),[ml] / [kg·min],0.83,166473,DB00468,Quinine
,10492795,clearance/fraction of quinine converted,"The estimated median (range) quinine clearance was 0.83 mL/kg/min (0.58-1.16), and 3OHQn clearance/fraction of quinine converted was 3.40 mL/kg/min (2.58-4.47).",Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492795/),[ml] / [kg·min],3.40,166474,DB00468,Quinine
,10492795,terminal elimination half-life,The estimated 3OHQn terminal elimination half-life was 21 h (16.5-32.5).,Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492795/),h,21,166475,DB00468,Quinine
,8097780,hepatic perfusate rate,"When administered as separate 1 mg doses, the hepatic clearances of quinine and quinidine were similar to the hepatic perfusate rate of 10 mL min-1.",Quinine impairs quinidine clearance in rat perfused liver. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],10,169880,DB00468,Quinine
,8097780,hepatic clearance,"When 1 mg of each was administered simultaneously, mean hepatic clearance of quinine was unchanged (9.00 +/- 2.20 mL min-1 separate dosage, n = 7; 6.87 +/- 1.77 mL min-1 simultaneous dosage, n = 7; P > 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],9.00,169881,DB00468,Quinine
,8097780,hepatic clearance,"When 1 mg of each was administered simultaneously, mean hepatic clearance of quinine was unchanged (9.00 +/- 2.20 mL min-1 separate dosage, n = 7; 6.87 +/- 1.77 mL min-1 simultaneous dosage, n = 7; P > 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],6.87,169882,DB00468,Quinine
,8097780,hepatic clearance,"By contrast, mean hepatic clearance of quinidine was reduced significantly by concomitant quinine (10.6 +/- 1.72 mL min-1 separate dosage, n = 7; 4.82 +/- 1.25 mL min-1 simultaneous dosage, n = 7; P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],10.6,169883,DB00468,Quinine
,8097780,hepatic clearance,"By contrast, mean hepatic clearance of quinidine was reduced significantly by concomitant quinine (10.6 +/- 1.72 mL min-1 separate dosage, n = 7; 4.82 +/- 1.25 mL min-1 simultaneous dosage, n = 7; P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],4.82,169884,DB00468,Quinine
,8097780,volumes of distribution,"There was no significant difference in volumes of distribution when each alkaloid was administered separately (131 +/- 46 mL quinine, 129 +/- 21 mL quinidine; P > 0.05) but concomitant quinine administration increased quinidine volume of distribution to 169 +/- 30 mL (P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),ml,131,169885,DB00468,Quinine
,8097780,volumes of distribution,"There was no significant difference in volumes of distribution when each alkaloid was administered separately (131 +/- 46 mL quinine, 129 +/- 21 mL quinidine; P > 0.05) but concomitant quinine administration increased quinidine volume of distribution to 169 +/- 30 mL (P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),ml,129,169886,DB00468,Quinine
,8097780,volume of distribution,"There was no significant difference in volumes of distribution when each alkaloid was administered separately (131 +/- 46 mL quinine, 129 +/- 21 mL quinidine; P > 0.05) but concomitant quinine administration increased quinidine volume of distribution to 169 +/- 30 mL (P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),ml,169,169887,DB00468,Quinine
,25406952,AUC,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[h·mg] / [l],27.93,170438,DB00468,Quinine
,25406952,AUC,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[h·mg] / [l],41.62,170439,DB00468,Quinine
,25406952,Cmax,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[mg] / [l],1.37,170440,DB00468,Quinine
,25406952,Cmax,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[mg] / [l],1.64,170441,DB00468,Quinine
,25406952,T1/2b,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),h,16.28,170442,DB00468,Quinine
,25406952,T1/2b,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),h,21.43,170443,DB00468,Quinine
,25406952,oral plasma clearance,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[l] / [h],23.17,170444,DB00468,Quinine
,25406952,oral plasma clearance,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 ± 8.04 vs. 41.62 ± 13.98 h·mg/L; Cmax: 1.37 ± 0.24 vs. 1.64 ± 0.38 mg/L; T1/2b: 16.28 ± 2.66 vs. 21.43 ± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 ± 6.49 vs. 16.00 ± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[l] / [h],16.00,170445,DB00468,Quinine
,12641404,fever subsidence times,The dosage schedule led to a rapid clinical response and reduced parasite clearance and fever subsidence times of (31.5 +/- 10.1 hours) and (31.4 +/- 11.1 hours).,Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12641404/),h,31.4,175608,DB00468,Quinine
,1596283,IC50,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,7.5,176859,DB00468,Quinine
,1596283,Ki,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,11.2,176860,DB00468,Quinine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,17.5,176861,DB00468,Quinine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,122,176862,DB00468,Quinine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,8.6,176863,DB00468,Quinine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,28.5,176864,DB00468,Quinine
,8848817,tmax,"The tmax (4.3 +/- 0.5 h) and elimination half-life (11.8 +/- 2.9 h) of quinine derived from saliva levels were comparable with those obtained from plasma levels (tmax = 2.8 +/- 0.2 h, t1/2 = 12.9 +/- 2.3 h).",Relationship between plasma and saliva quinine levels in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848817/),h,4.3,177523,DB00468,Quinine
,8848817,elimination half-life,"The tmax (4.3 +/- 0.5 h) and elimination half-life (11.8 +/- 2.9 h) of quinine derived from saliva levels were comparable with those obtained from plasma levels (tmax = 2.8 +/- 0.2 h, t1/2 = 12.9 +/- 2.3 h).",Relationship between plasma and saliva quinine levels in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848817/),h,11.8,177524,DB00468,Quinine
,8848817,tmax,"The tmax (4.3 +/- 0.5 h) and elimination half-life (11.8 +/- 2.9 h) of quinine derived from saliva levels were comparable with those obtained from plasma levels (tmax = 2.8 +/- 0.2 h, t1/2 = 12.9 +/- 2.3 h).",Relationship between plasma and saliva quinine levels in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848817/),h,2.8,177525,DB00468,Quinine
,8848817,t1/2,"The tmax (4.3 +/- 0.5 h) and elimination half-life (11.8 +/- 2.9 h) of quinine derived from saliva levels were comparable with those obtained from plasma levels (tmax = 2.8 +/- 0.2 h, t1/2 = 12.9 +/- 2.3 h).",Relationship between plasma and saliva quinine levels in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848817/),h,12.9,177526,DB00468,Quinine
,8848817,saliva/plasma quinine,The mean saliva/plasma quinine concentration ratio was 0.24 +/- 0.02.,Relationship between plasma and saliva quinine levels in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848817/),,0.24,177527,DB00468,Quinine
,8848817,concentration ratio,The mean saliva/plasma quinine concentration ratio was 0.24 +/- 0.02.,Relationship between plasma and saliva quinine levels in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848817/),,0.24,177528,DB00468,Quinine
,20717655,AUCs,"During phase I, the AUCs (mean ± SD) of quinine and its major metaboplite, 3-hydroxyquinine, in pregnant women were 428.2 ± 132.4 and 27.8 ± 14.1 μmol l(-1) h(-1) respectively.",Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),[μM] / [h·l],428.2,180938,DB00468,Quinine
,20717655,AUCs,"During phase I, the AUCs (mean ± SD) of quinine and its major metaboplite, 3-hydroxyquinine, in pregnant women were 428.2 ± 132.4 and 27.8 ± 14.1 μmol l(-1) h(-1) respectively.",Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),[μM] / [h·l],27.8,180939,DB00468,Quinine
,20717655,AUCs,In non-pregnant women the AUCs of quinine and 3-hydroxyquinine were 517.8 ± 100.0 and 32.3 ± 15.3 μmol l(-1) h(-1).,Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),[μM] / [h·l],517.8,180940,DB00468,Quinine
,20717655,AUCs,In non-pregnant women the AUCs of quinine and 3-hydroxyquinine were 517.8 ± 100.0 and 32.3 ± 15.3 μmol l(-1) h(-1).,Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),[μM] / [h·l],32.3,180941,DB00468,Quinine
,20717655,AUC ratios,"In pregnant women the mean (90% confidence interval) AUC ratios of phase I to phase II of quinine and 3-hydroxyquinine were 1.6 (0.61, 4.22) and 1.01 (0.18, 5.60).",Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),,1.6,180942,DB00468,Quinine
,20717655,AUC ratios,"In pregnant women the mean (90% confidence interval) AUC ratios of phase I to phase II of quinine and 3-hydroxyquinine were 1.6 (0.61, 4.22) and 1.01 (0.18, 5.60).",Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),,1.01,180943,DB00468,Quinine
,20717655,AUC ratios,"In non-pregnant women, the AUC ratios of phase I to phase II of quinine and 3-hydroxyquinine were 1.93 (1.74, 2.15) and 1.19 (0.95, 1.47).",Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),,1.93,180944,DB00468,Quinine
,20717655,AUC ratios,"In non-pregnant women, the AUC ratios of phase I to phase II of quinine and 3-hydroxyquinine were 1.93 (1.74, 2.15) and 1.19 (0.95, 1.47).",Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20717655/),,1.19,180945,DB00468,Quinine
,8824690,V,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),[1] / [kg],0.44,185299,DB00468,Quinine
,8824690,CL,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),[1] / [h·kg],0.13,185300,DB00468,Quinine
,8824690,Cmax,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),1/[mg1],106,185301,DB00468,Quinine
,8824690,t1/2,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),h,3.4,185302,DB00468,Quinine
,8824690,base deficit,"4 DCA decreased venous plasma lactate concentrations by 42% of baseline values 8 h after admission, normalized arterial pH from a mean(s.d.) of 7.367(0.063) to 7.39(0.1), and decreased the calculated base deficit from 9.2(7.3) mEq 1-1 to 6.4(10.4) mEq 1-1.",The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),,9.2,185303,DB00468,Quinine
,8824690,base deficit,"4 DCA decreased venous plasma lactate concentrations by 42% of baseline values 8 h after admission, normalized arterial pH from a mean(s.d.) of 7.367(0.063) to 7.39(0.1), and decreased the calculated base deficit from 9.2(7.3) mEq 1-1 to 6.4(10.4) mEq 1-1.",The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),,6,185304,DB00468,Quinine
,14638485,peak concentrations,"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),mM,"1,905",188372,DB00468,Quinine
,14638485,peak concentrations,"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),mM,955,188373,DB00468,Quinine
,14638485,clearance (CL/F),"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),[l] / [h·kg],1.11,188374,DB00468,Quinine
,14638485,clearance (CL/F),"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),[l] / [h·kg],2.76,188375,DB00468,Quinine
,14638485,time to Cmax,"In the acute phase, the time to Cmax was significantly shorter after oral administration (median, 1 h; range, 0.5 to 3.0 h) than after intramuscular administration (median, 8 h; range, 4 to 24 h) (P=0.001).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),h,1,188376,DB00468,Quinine
,14638485,time to Cmax,"In the acute phase, the time to Cmax was significantly shorter after oral administration (median, 1 h; range, 0.5 to 3.0 h) than after intramuscular administration (median, 8 h; range, 4 to 24 h) (P=0.001).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),h,8,188377,DB00468,Quinine
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kg·min],9.1,192659,DB00468,Quinine
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kg·min],7.6,192660,DB00468,Quinine
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,9.6,192661,DB00468,Quinine
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,11.5,192662,DB00468,Quinine
,2653061,fever clearance time,"The mean fever clearance time was 44.1 hr, and the mean parasite clearance time was 59.6 hr.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),h,44.1,196748,DB00468,Quinine
,2653061,parasite clearance time,"The mean fever clearance time was 44.1 hr, and the mean parasite clearance time was 59.6 hr.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),h,59.6,196749,DB00468,Quinine
,2653061,peak quinine level,"A mean peak quinine level of 9.7 ppm was attained after the second dose of quinine, and the minimum concentration was maintained at 5-7 ppm during the 2nd and 3rd hospital days.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),ppm,9.7,196750,DB00468,Quinine
,2653061,minimum concentration,"A mean peak quinine level of 9.7 ppm was attained after the second dose of quinine, and the minimum concentration was maintained at 5-7 ppm during the 2nd and 3rd hospital days.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),ppm,5-7,196751,DB00468,Quinine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],7.54,201030,DB00468,Quinine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],13.10,201031,DB00468,Quinine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],0.84,201032,DB00468,Quinine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],2.51,201033,DB00468,Quinine
,12957180,recovery,The limit of determination was 10 nM for both quinine and 3-hydroxyquinine and the recovery varied between 78 and 109%.,High-performance liquid chromatographic method for the determination of quinine and 3-hydroxyquinine in blood samples dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12957180/),%,78 and 109,203746,DB00468,Quinine
,11187897,MTD,The MTD of cinchonine administered by continuous i.v. infusion was 30 mg/kg/d.,"Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11187897/),[mg] / [d·kg],30,204899,DB00468,Quinine
,19298689,AUC,"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),[h·mg] / [l],53.29,204979,DB00468,Quinine
,19298689,AUC,"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),[h·mg] / [l],35.48,204980,DB00468,Quinine
,19298689,C(max),"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),[mg] / [l],2.83,204981,DB00468,Quinine
,19298689,C(max),"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),[mg] / [l],1.81,204982,DB00468,Quinine
,19298689,T((1/2)beta),"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),h,11.35,204983,DB00468,Quinine
,19298689,T((1/2)beta),"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),h,8.54,204984,DB00468,Quinine
,19298689,oral plasma clearance,"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),[l] / [h],11.32,204985,DB00468,Quinine
,19298689,oral plasma clearance,"Administration of quinine plus nevirapine resulted in significant decreases (P < 0.01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l; C(max): 2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h), while the oral plasma clearance markedly increased (11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h).",Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298689/),[l] / [h],16.97,204986,DB00468,Quinine
,14576102,fever clearance time,"The median fever clearance time was 58.5 h, and the mean +/- standard deviation parasite clearance time was 73 +/- 24 h.",Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),h,58.5,205934,DB00468,Quinine
,14576102,parasite clearance time,"The median fever clearance time was 58.5 h, and the mean +/- standard deviation parasite clearance time was 73 +/- 24 h.",Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),h,73,205935,DB00468,Quinine
<,14576102,area under the concentration-time curve from 3 to 7 days,Patients for whom the area under the concentration-time curve from 3 to 7 days for quinine in plasma was <20 microg.,Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),μg,20,205936,DB00468,Quinine
,14576102,minimum parasiticidal concentration,Modeling of these data suggested an average minimum parasiticidal concentration of quinine in plasma of 3.4 microg/ml and an MIC of 0.7 microg/ml for uncomplicated falciparum malaria in Thailand.,Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),[μg] / [ml],3.4,205937,DB00468,Quinine
,14576102,MIC,Modeling of these data suggested an average minimum parasiticidal concentration of quinine in plasma of 3.4 microg/ml and an MIC of 0.7 microg/ml for uncomplicated falciparum malaria in Thailand.,Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),[μg] / [ml],0.7,205938,DB00468,Quinine
,3882924,half-life,"The mean (+/- SD) half-life of quinine was 11.1 +/- 4.8 hours, and the volume of distribution was 1.39 +/- 0.37 L/kg.",Pharmacokinetics of quinine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3882924/),h,11.1,209229,DB00468,Quinine
,3882924,volume of distribution,"The mean (+/- SD) half-life of quinine was 11.1 +/- 4.8 hours, and the volume of distribution was 1.39 +/- 0.37 L/kg.",Pharmacokinetics of quinine in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3882924/),[l] / [kg],1.39,209230,DB00468,Quinine
,8290470,flow rate,"The derivative (7-OH quinoline; DER) and the internal standard (quinine-bisulfate; IS) were separated on a 10-micron particle, 8 mm x 10-cm C18 cartridge in conjunction with a radial compression system using a mixture of 0.05 M dibasic ammonium phosphate solution (pH 2.5):acetonitrile:methanol (92:6:2) at a flow rate of 3 mL/min as a mobile phase.",Determination of acrolein in urine by liquid chromatography and fluorescence detection of its quinoline derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290470/),[ml] / [min],3,210630,DB00468,Quinine
,8290470,retention times,"The retention times of DER and IS under these conditions were 4.3 and 26 min, respectively, and no interference in the assay from any endogenous substance or other concomitantly used drug was observed.",Determination of acrolein in urine by liquid chromatography and fluorescence detection of its quinoline derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290470/),min,4.3,210631,DB00468,Quinine
,8290470,retention times,"The retention times of DER and IS under these conditions were 4.3 and 26 min, respectively, and no interference in the assay from any endogenous substance or other concomitantly used drug was observed.",Determination of acrolein in urine by liquid chromatography and fluorescence detection of its quinoline derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290470/),min,26,210632,DB00468,Quinine
,3879657,absorption half-times,"Absorption was rapid with both dose schedules used; mean absorption half-times were 1.5 and 1.8 hr, and plasma mefloquine concentrations exceeded 200 ng/g within 3 hr of completing administration in all but one exceptionally ill patient who died 40 hr later.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),h,1.5,211361,DB00468,Quinine
,3879657,absorption half-times,"Absorption was rapid with both dose schedules used; mean absorption half-times were 1.5 and 1.8 hr, and plasma mefloquine concentrations exceeded 200 ng/g within 3 hr of completing administration in all but one exceptionally ill patient who died 40 hr later.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),h,1.8,211362,DB00468,Quinine
,3879657,Steady state plasma concentrations,"Steady state plasma concentrations over 7 days ranged from 300 to 1,050 (mean 561) ng/g.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),[ng] / [g],561,211363,DB00468,Quinine
,6626434,Peak plasma concentrations,Peak plasma concentrations (mean +/- 1 s.d.) after the infusion were 5.1 +/- 1.3 mg 1(-1).,Quinine disposition kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626434/),mg,5.1,214748,DB00468,Quinine
,6626434,"distribution half-time (t 1/2, lambda 1)","Pharmacokinetic analysis fitted a two compartment open model in each case; distribution half-time (t 1/2, lambda 1) was 1.89 +/- 0.54 min (mean +/- 1 s.d.), elimination half-time (t 1/2, z) 11.1 +/- 2.1 h, apparent volume of the central compartment (V1) 0.57 +/- 0.32 1 kg-1, total apparent volume of distribution 1.80 +/- 0.37 1 kg-1 and total clearance 1.92 +/- 0.45 ml min-1 kg-1.",Quinine disposition kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626434/),min,1.89,214749,DB00468,Quinine
,6626434,"elimination half-time (t 1/2, z)","Pharmacokinetic analysis fitted a two compartment open model in each case; distribution half-time (t 1/2, lambda 1) was 1.89 +/- 0.54 min (mean +/- 1 s.d.), elimination half-time (t 1/2, z) 11.1 +/- 2.1 h, apparent volume of the central compartment (V1) 0.57 +/- 0.32 1 kg-1, total apparent volume of distribution 1.80 +/- 0.37 1 kg-1 and total clearance 1.92 +/- 0.45 ml min-1 kg-1.",Quinine disposition kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626434/),h,11.1,214750,DB00468,Quinine
,6626434,apparent volume of the central compartment (V1),"Pharmacokinetic analysis fitted a two compartment open model in each case; distribution half-time (t 1/2, lambda 1) was 1.89 +/- 0.54 min (mean +/- 1 s.d.), elimination half-time (t 1/2, z) 11.1 +/- 2.1 h, apparent volume of the central compartment (V1) 0.57 +/- 0.32 1 kg-1, total apparent volume of distribution 1.80 +/- 0.37 1 kg-1 and total clearance 1.92 +/- 0.45 ml min-1 kg-1.",Quinine disposition kinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626434/),[1] / [kg],0.57,214751,DB00468,Quinine
,6626434,total apparent volume of distribution,"Pharmacokinetic analysis fitted a two compartment open model in each case; distribution half-time (t 1/2, lambda 1) was 1.89 +/- 0.54 min (mean +/- 1 s.d.), elimination half-time (t 1/2, z) 11.1 +/- 2.1 h, apparent volume of the central compartment (V1) 0.57 +/- 0.32 1 kg-1, total apparent volume of distribution 1.80 +/- 0.37 1 kg-1 and total clearance 1.92 +/- 0.45 ml min-1 kg-1.",Quinine disposition kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626434/),[1] / [kg],1.80,214752,DB00468,Quinine
,6626434,total clearance,"Pharmacokinetic analysis fitted a two compartment open model in each case; distribution half-time (t 1/2, lambda 1) was 1.89 +/- 0.54 min (mean +/- 1 s.d.), elimination half-time (t 1/2, z) 11.1 +/- 2.1 h, apparent volume of the central compartment (V1) 0.57 +/- 0.32 1 kg-1, total apparent volume of distribution 1.80 +/- 0.37 1 kg-1 and total clearance 1.92 +/- 0.45 ml min-1 kg-1.",Quinine disposition kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626434/),[ml] / [kg·min],1.92,214753,DB00468,Quinine
,3543604,t1/2 beta,"In healthy subjects, quinine is rapidly eliminated (t1/2 beta: 6-12 h).","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),h,6-12,215080,DB00468,Quinine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-50,215081,DB00468,Quinine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-33,215082,DB00468,Quinine
,3543604,t1/2 beta,"In healthy subjects, the t1/2 beta of this metabolite is 9 to 18 days in plasma.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,9 to 18,215083,DB00468,Quinine
,3543604,elimination half-life,Halofantrine has an elimination half-life of between 1.3 and 6.6 days.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,1.3 and 6.6,215084,DB00468,Quinine
,3543604,elimination half-life,"In rabbits, the elimination half-life in plasma was found to be 40 min.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),min,40,215085,DB00468,Quinine
,2091334,peak concentrations,Quinine was well absorbed reaching mean peak concentrations of 15.6 (standard deviation [SD] 4.5) mg/litre in a median time of 3 h (range 1-6 h).,The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091334/),[mg] / [l],15.6,220744,DB00468,Quinine
,2091334,time,Quinine was well absorbed reaching mean peak concentrations of 15.6 (standard deviation [SD] 4.5) mg/litre in a median time of 3 h (range 1-6 h).,The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091334/),h,3,220745,DB00468,Quinine
,2091334,systemic clearance (Cl/F),The mean estimated systemic clearance (Cl/F) was 0.89 (SD 0.81) ml/kg/min and the mean elimination half life was 18.8 (SD 8.0) h.,The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091334/),[ml] / [kg·min],0.89,220746,DB00468,Quinine
,2091334,elimination half life,The mean estimated systemic clearance (Cl/F) was 0.89 (SD 0.81) ml/kg/min and the mean elimination half life was 18.8 (SD 8.0) h.,The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091334/),h,18.8,220747,DB00468,Quinine
,2091334,peak,Mean peak and trough plasma concentrations after subsequent intramuscular doses ranged between 11.1 and 15.1 mg/litre.,The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091334/),[mg] / [l],11.1 and 15.1,220748,DB00468,Quinine
,6176784,total body clearance (ClT),"The total body clearance (ClT) of quinidine, 3.58 +/- 1.96 (SD) ml/kg/min, was 56% slower than that of quinine, 8.11 +/- 3.03 ml/kg/min, with p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),[ml] / [kg·min],3.58,221113,DB00468,Quinine
,6176784,total body clearance (ClT),"The total body clearance (ClT) of quinidine, 3.58 +/- 1.96 (SD) ml/kg/min, was 56% slower than that of quinine, 8.11 +/- 3.03 ml/kg/min, with p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),[ml] / [kg·min],8.11,221114,DB00468,Quinine
,6176784,half-life (t1/2),"Quinine half-life (t1/2), 6.58 +/- 3.3 h, was 54% less than that of quinidine, 14.4 +/- 4.10 h, p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),h,6.58,221115,DB00468,Quinine
,6176784,half-life (t1/2),"Quinine half-life (t1/2), 6.58 +/- 3.3 h, was 54% less than that of quinidine, 14.4 +/- 4.10 h, p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),h,14.4,221116,DB00468,Quinine
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.10,221673,DB00468,Quinine
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.25,221674,DB00468,Quinine
,12606644,maximum degree of inhibition,"Inhibition of both (+)-M1 formation clearance (CL(M10)) and CL(ME0) were modeled by an inhibitory E(MAX) model, and the estimates (relative standard error) of the maximum degree of inhibition (E(MAX)) and IC(50), plasma concentration of Q eliciting half of E(MAX) for CL(M10) and CL(ME0), were 0.94 (0.04), 97 (0.51) ng/ml, and 48 (0.42) ng/ml, respectively.",Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12606644/),[ng] / [ml],0.94,222715,DB00468,Quinine
,12606644,IC(50),"Inhibition of both (+)-M1 formation clearance (CL(M10)) and CL(ME0) were modeled by an inhibitory E(MAX) model, and the estimates (relative standard error) of the maximum degree of inhibition (E(MAX)) and IC(50), plasma concentration of Q eliciting half of E(MAX) for CL(M10) and CL(ME0), were 0.94 (0.04), 97 (0.51) ng/ml, and 48 (0.42) ng/ml, respectively.",Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12606644/),[ng] / [ml],97,222716,DB00468,Quinine
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB00468,Quinine
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB00468,Quinine
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB00468,Quinine
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB00468,Quinine
,15890479,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) of torasemide was significantly greater in rats pretreated with SKF 525-A (a non-specific CYP isozyme inhibitor in rats) than that in control rats (3570 versus 1350 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],3570,223408,DB00468,Quinine
,15890479,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) of torasemide was significantly greater in rats pretreated with SKF 525-A (a non-specific CYP isozyme inhibitor in rats) than that in control rats (3570 versus 1350 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1350,223409,DB00468,Quinine
,15890479,AUC,"However, in rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the AUC was significantly smaller than that in control rats (1290 versus 1590 microg min/ml).",Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1290,223410,DB00468,Quinine
,15890479,AUC,"However, in rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the AUC was significantly smaller than that in control rats (1290 versus 1590 microg min/ml).",Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1590,223411,DB00468,Quinine
,15890479,AUC,It has been reported from our laboratories that in rats pretreated with sulfaphenazole (a main inhibitor of CYP2C11 in rats) the AUC was significantly greater than that in control rats (2970 versus 1610 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],2970,223412,DB00468,Quinine
,15890479,AUC,It has been reported from our laboratories that in rats pretreated with sulfaphenazole (a main inhibitor of CYP2C11 in rats) the AUC was significantly greater than that in control rats (2970 versus 1610 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1610,223413,DB00468,Quinine
,1618248,absorption half-life,"Quinine was rapidly and almost completely absorbed after an oral dose, with absorption half-life of 0.53 h, a tmax of 1-3 h and a bioavailability of 88%.","Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618248/),h,0.53,225175,DB00468,Quinine
,1618248,tmax,"Quinine was rapidly and almost completely absorbed after an oral dose, with absorption half-life of 0.53 h, a tmax of 1-3 h and a bioavailability of 88%.","Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618248/),h,1-3,225176,DB00468,Quinine
,1618248,bioavailability,"Quinine was rapidly and almost completely absorbed after an oral dose, with absorption half-life of 0.53 h, a tmax of 1-3 h and a bioavailability of 88%.","Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618248/),%,88,225177,DB00468,Quinine
,1618248,apparent volume of distribution,Analysis of the i.v. data gave an apparent volume of distribution of 3.6 l.kg-1 and a plasma clearance of 0.19 l.kg-1.h-1.,"Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618248/),[l] / [kg],3.6,225178,DB00468,Quinine
,1618248,plasma clearance,Analysis of the i.v. data gave an apparent volume of distribution of 3.6 l.kg-1 and a plasma clearance of 0.19 l.kg-1.h-1.,"Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618248/),[l] / [h·kg],0.19,225179,DB00468,Quinine
,11802092,overall levels,"From the second day of treatment, overall levels varied from 2.33 to 14.29 microg/mL; the peak concentrations showed values from 4.22 to 16.89 microg/mL, showing the efficacy of the therapeutic regimen used.",Drug monitoring of quinine in men with nonsevere falciparum malaria: study in the Amazon region of Brazil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802092/),,2.33 to 14.29,225528,DB00468,Quinine
,11802092,peak concentrations,"From the second day of treatment, overall levels varied from 2.33 to 14.29 microg/mL; the peak concentrations showed values from 4.22 to 16.89 microg/mL, showing the efficacy of the therapeutic regimen used.",Drug monitoring of quinine in men with nonsevere falciparum malaria: study in the Amazon region of Brazil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802092/),[μg] / [ml],4.22 to 16.89,225529,DB00468,Quinine
,9342585,plasma protein binding,"The mean plasma protein binding of 3-hydroxyquinine was 46%, which was significantly lower than that of quinine (90.5%) or dihydroquinine (90.5%).",A study of the factors affecting the metabolic clearance of quinine in malaria. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342585/),%,46,227091,DB00468,Quinine
,9342585,plasma protein binding,"The mean plasma protein binding of 3-hydroxyquinine was 46%, which was significantly lower than that of quinine (90.5%) or dihydroquinine (90.5%).",A study of the factors affecting the metabolic clearance of quinine in malaria. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342585/),%,90.5,227092,DB00468,Quinine
greater,1550696,Peak blood PB concentrations,"3. Peak blood PB concentrations were equal to or greater than 15 mg l-1 in 27% of the patients on quinine and 23% of those not on quinine; a concentration of 10 mg l-1 was achieved or exceeded by 100% and 92% of each group, respectively, and was maintained for 39 +/- 24 h (mean +/- s.d.), and 33 +/- 21 h, respectively.",Prophylactic phenobarbitone in young children with severe falciparum malaria: pharmacokinetics and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550696/),[mg] / [l],15,227841,DB00468,Quinine
,8485027,terminal elimination half-life,The terminal elimination half-life was prolonged (17 and 15 vs 10 h) and clearance was lower (2.9 and 2.3 vs 3.5 ml min-1 kg-1).,The pharmacokinetics of quinine in patients with hepatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485027/),h,17,228034,DB00468,Quinine
,8485027,terminal elimination half-life,The terminal elimination half-life was prolonged (17 and 15 vs 10 h) and clearance was lower (2.9 and 2.3 vs 3.5 ml min-1 kg-1).,The pharmacokinetics of quinine in patients with hepatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485027/),h,15,228035,DB00468,Quinine
,8485027,terminal elimination half-life,The terminal elimination half-life was prolonged (17 and 15 vs 10 h) and clearance was lower (2.9 and 2.3 vs 3.5 ml min-1 kg-1).,The pharmacokinetics of quinine in patients with hepatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485027/),h,10,228036,DB00468,Quinine
,8485027,clearance,The terminal elimination half-life was prolonged (17 and 15 vs 10 h) and clearance was lower (2.9 and 2.3 vs 3.5 ml min-1 kg-1).,The pharmacokinetics of quinine in patients with hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485027/),[ml] / [kg·min],2.9,228037,DB00468,Quinine
,8485027,clearance,The terminal elimination half-life was prolonged (17 and 15 vs 10 h) and clearance was lower (2.9 and 2.3 vs 3.5 ml min-1 kg-1).,The pharmacokinetics of quinine in patients with hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485027/),[ml] / [kg·min],2.3,228038,DB00468,Quinine
,8485027,clearance,The terminal elimination half-life was prolonged (17 and 15 vs 10 h) and clearance was lower (2.9 and 2.3 vs 3.5 ml min-1 kg-1).,The pharmacokinetics of quinine in patients with hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485027/),[ml] / [kg·min],3.5,228039,DB00468,Quinine
,20233197,C(max),Concurrent ritonavir administration resulted in about fourfold increases in both the C(max) and AUC(T)[C(max) 2.79 +/- 0.22 vs.,Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,2.79,232150,DB00468,Quinine
,20233197,AUC,"10.72 +/- 0.32 mg l(-1), 95% confidence interval (CI) 7.81, 8.04; AUC 50.06 +/- 2.52 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,50.06,232151,DB00468,Quinine
,20233197,elimination half-life,"220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),h,11.15,232152,DB00468,Quinine
,20233197,elimination half-life,"220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),h,13.37,232153,DB00468,Quinine
,20233197,CL/F,"220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,12.01,232154,DB00468,Quinine
,20233197,AUC,"Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,1.35,232155,DB00468,Quinine
,20233197,AUC,"Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,0.13,232156,DB00468,Quinine
,20233197,C(max),"Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,1.80,232157,DB00468,Quinine
,20233197,AUC(0-48h),0.96 +/- 0.09 mg l(-1)) and AUC(0-48h) (62.80 +/- 6.30 vs.,Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,62.80,232158,DB00468,Quinine
,34341510,IC50,"Among 6 known K2P channel modulators tested (DCPIB, quinine, fluoxetine, ML365, ML335, and TKDC), ML365 was the most potent TWIK2 channel blocker with an IC50 value of 4.07 ± 1.5 μM.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),μM,4.07,233069,DB00468,Quinine
,34341510,F,"In a preliminary pharmacokinetic study conducted in rats, ML365 showed good absolute oral bioavailability with F value of 22.49%.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),%,22.49,233070,DB00468,Quinine
,8471402,terminal elimination half-time,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),h,5.7,234616,DB00468,Quinine
,8471402,terminal elimination half-time,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),h,9.9,234617,DB00468,Quinine
,8471402,volume of distribution at steady state (Vss),"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[1] / [kg],3.5,234618,DB00468,Quinine
,8471402,volume of distribution at steady state (Vss),"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[1] / [kg],3.1,234619,DB00468,Quinine
,8471402,% free drug,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),%,22.8,234620,DB00468,Quinine
,8471402,% free drug,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),%,9.4,234621,DB00468,Quinine
,8471402,Total clearance,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kg·min],7.7,234622,DB00468,Quinine
,8471402,Total clearance,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kg·min],3.4,234623,DB00468,Quinine
,8471402,clearance of unbound drug,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kg·min],32.2,234624,DB00468,Quinine
,8471402,clearance of unbound drug,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kg·min],29.9,234625,DB00468,Quinine
,8471402,keo,"4. Both drugs produced prolongation of the rate-corrected QT interval (QTc), with similar rates of elimination from the cardiac conduction 'effect' compartment (keo; 4.14 [0.03-15.33] h-1 for quinine, 3.74 [1.63-13.14] h-1 for quinidine, P > 0.19).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),1/[h],4.14,234626,DB00468,Quinine
,8471402,keo,"4. Both drugs produced prolongation of the rate-corrected QT interval (QTc), with similar rates of elimination from the cardiac conduction 'effect' compartment (keo; 4.14 [0.03-15.33] h-1 for quinine, 3.74 [1.63-13.14] h-1 for quinidine, P > 0.19).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),1/[h],3.74,234627,DB00468,Quinine
,1969945,terminal half-life,"However, on increasing dose, the terminal half-life of free and total quinine showed marked increases ranging from 12.4 +/- 3.7 min at 6.25 mg to 176.0 +/- 153 min at 25 mg (total quinine).",The disposition of quinine in the rat isolated perfused liver: effect of dose size. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1969945/),min,12.4,235334,DB00468,Quinine
,1969945,terminal half-life,"However, on increasing dose, the terminal half-life of free and total quinine showed marked increases ranging from 12.4 +/- 3.7 min at 6.25 mg to 176.0 +/- 153 min at 25 mg (total quinine).",The disposition of quinine in the rat isolated perfused liver: effect of dose size. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1969945/),min,176.0,235335,DB00468,Quinine
,1969945,extraction,"At 10 min post dosage, quinine extraction at the 6.25 mg dose (56 +/- 16.3%) was more than twice that of the highest dose (25 mg, 25.0 +/- 6.5%).",The disposition of quinine in the rat isolated perfused liver: effect of dose size. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1969945/),%,56,235336,DB00468,Quinine
,1969945,extraction,"At 10 min post dosage, quinine extraction at the 6.25 mg dose (56 +/- 16.3%) was more than twice that of the highest dose (25 mg, 25.0 +/- 6.5%).",The disposition of quinine in the rat isolated perfused liver: effect of dose size. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1969945/),%,25.0,235337,DB00468,Quinine
,1682445,clearance (CL),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [h·kg],4.49,236435,DB00468,Quinine
,1682445,clearance (CL),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [h·kg],1.38,236436,DB00468,Quinine
,1682445,volume of distribution (Vd),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [kg],42.6,236437,DB00468,Quinine
,1682445,volume of distribution (Vd),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [kg],28.9,236438,DB00468,Quinine
,1682445,elimination half-life (t1/2),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,7.1,236439,DB00468,Quinine
,1682445,elimination half-life (t1/2),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,15.9,236440,DB00468,Quinine
,1682445,CL,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [h·kg],3.95,236441,DB00468,Quinine
,1682445,CL,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [h·kg],1.89,236442,DB00468,Quinine
,1682445,t1/2,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,5.1,236443,DB00468,Quinine
,1682445,t1/2,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,10.1,236444,DB00468,Quinine
,8735679,time required,"3. The decrease in parasitaemia did not differ between the three groups and the time required for a 50% fall in parasitaemia relative to baseline was 12.3 +/- 5.4, 18.2 +/- 6.1 and 14.5 +/- 4.2 h in the intrarectal, intramuscular and intravenous treatment groups, respectively.",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h,12.3,238020,DB00468,Quinine
,8735679,time required,"3. The decrease in parasitaemia did not differ between the three groups and the time required for a 50% fall in parasitaemia relative to baseline was 12.3 +/- 5.4, 18.2 +/- 6.1 and 14.5 +/- 4.2 h in the intrarectal, intramuscular and intravenous treatment groups, respectively.",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h,18.2,238021,DB00468,Quinine
,8735679,time required,"3. The decrease in parasitaemia did not differ between the three groups and the time required for a 50% fall in parasitaemia relative to baseline was 12.3 +/- 5.4, 18.2 +/- 6.1 and 14.5 +/- 4.2 h in the intrarectal, intramuscular and intravenous treatment groups, respectively.",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h,14.5,238022,DB00468,Quinine
,8735679,Parasitaemia,"Parasitaemia expressed as a percentage of initial values was not significantly different in the three groups after 48 h of treatment (7.4 +/- 16.0, 4.1 +/- 4.2 and 2.2 +/- 3.8% in the intrarectal, intramuscular and intravenous treatment groups, respectively).",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),%,7.4,238023,DB00468,Quinine
,8735679,Parasitaemia,"Parasitaemia expressed as a percentage of initial values was not significantly different in the three groups after 48 h of treatment (7.4 +/- 16.0, 4.1 +/- 4.2 and 2.2 +/- 3.8% in the intrarectal, intramuscular and intravenous treatment groups, respectively).",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),%,4.1,238024,DB00468,Quinine
,8735679,Parasitaemia,"Parasitaemia expressed as a percentage of initial values was not significantly different in the three groups after 48 h of treatment (7.4 +/- 16.0, 4.1 +/- 4.2 and 2.2 +/- 3.8% in the intrarectal, intramuscular and intravenous treatment groups, respectively).",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),%,2.2,238025,DB00468,Quinine
,8735679,tmax,5. The tmax occurred later after intrarectal (4.1 +/- 2.4 h) and intravenous infusion (3.8 +/- 0.5 h) than after intramuscular injection (1.6 +/- 1.3 h) (P = 0.02).,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h,4.1,238026,DB00468,Quinine
,8735679,tmax,5. The tmax occurred later after intrarectal (4.1 +/- 2.4 h) and intravenous infusion (3.8 +/- 0.5 h) than after intramuscular injection (1.6 +/- 1.3 h) (P = 0.02).,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h,3.8,238027,DB00468,Quinine
,8735679,tmax,5. The tmax occurred later after intrarectal (4.1 +/- 2.4 h) and intravenous infusion (3.8 +/- 0.5 h) than after intramuscular injection (1.6 +/- 1.3 h) (P = 0.02).,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h,1.6,238028,DB00468,Quinine
,8735679,Cmax,Cmax was lower with the intrarectal (3.0 +/- 1.0 mg 1(-1)) and intramuscular routes (3.2 +/- 0.7 mg 1(-1)) than with the intravenous route (5.1 +/- 1.4 mg 1(-1)) (P = 0.003).,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),mg,3.0,238029,DB00468,Quinine
,8735679,Cmax,Cmax was lower with the intrarectal (3.0 +/- 1.0 mg 1(-1)) and intramuscular routes (3.2 +/- 0.7 mg 1(-1)) than with the intravenous route (5.1 +/- 1.4 mg 1(-1)) (P = 0.003).,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),mg,3.2,238030,DB00468,Quinine
,8735679,Cmax,Cmax was lower with the intrarectal (3.0 +/- 1.0 mg 1(-1)) and intramuscular routes (3.2 +/- 0.7 mg 1(-1)) than with the intravenous route (5.1 +/- 1.4 mg 1(-1)) (P = 0.003).,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),mg,5.1,238031,DB00468,Quinine
,8735679,"Areas under the curve (AUC(0, 8 h))","Areas under the curve (AUC(0, 8 h)) were smaller with intrarectal (17.0 +/- 7 mg 1(-1) h) and intramuscular routes (19.4 +/- 4.8 mg 1(-1)) than with the intravenous route (27.8 +/- 8.2 mg 1(-1) h) (P = 0.02).",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h·mg,17.0,238032,DB00468,Quinine
,8735679,"Areas under the curve (AUC(0, 8 h))","Areas under the curve (AUC(0, 8 h)) were smaller with intrarectal (17.0 +/- 7 mg 1(-1) h) and intramuscular routes (19.4 +/- 4.8 mg 1(-1)) than with the intravenous route (27.8 +/- 8.2 mg 1(-1) h) (P = 0.02).",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),mg,19.4,238033,DB00468,Quinine
,8735679,"Areas under the curve (AUC(0, 8 h))","Areas under the curve (AUC(0, 8 h)) were smaller with intrarectal (17.0 +/- 7 mg 1(-1) h) and intramuscular routes (19.4 +/- 4.8 mg 1(-1)) than with the intravenous route (27.8 +/- 8.2 mg 1(-1) h) (P = 0.02).",Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),h·mg,27.8,238034,DB00468,Quinine
,8735679,bioavailability,The approximate bioavailability of intrarectal quinine from 0 to 8 h was 36% vs intravenous quinine and 51% vs intramuscular quinine.,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),%,36,238035,DB00468,Quinine
,8735679,bioavailability,The approximate bioavailability of intrarectal quinine from 0 to 8 h was 36% vs intravenous quinine and 51% vs intramuscular quinine.,Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735679/),%,51,238036,DB00468,Quinine
,2706191,half-life,Activated charcoal lowered quinine half-life from 8.23 +/- 0.57 s.d. h to 4.55 +/- 0.15 s.d. h (P less than 0.001) and increased its oral clearance by 56%.,Effect of oral activated charcoal on quinine elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706191/),,8.23,239034,DB00468,Quinine
,2706191,half-life,Activated charcoal lowered quinine half-life from 8.23 +/- 0.57 s.d. h to 4.55 +/- 0.15 s.d. h (P less than 0.001) and increased its oral clearance by 56%.,Effect of oral activated charcoal on quinine elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706191/),d·h·s,4.55,239035,DB00468,Quinine
,15819461,t(max),QN was rapidly absorbed after the two oral formulations with average t(max) of 2.67 h for both capsule and tablet.,Absolute bioavailability of quinine formulations in Nigeria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15819461/),h,2.67,240813,DB00468,Quinine
,15819461,elimination half-life,The mean elimination half-life of QN from the i.v. and oral dosage forms varied between 10 and 13.5 hr and were not statistically different (P > 0.05).,Absolute bioavailability of quinine formulations in Nigeria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15819461/),h,10 and 13.5,240814,DB00468,Quinine
,15819461,absolute bioavailability (F),"The absolute bioavailability (F) were 73% (C.l., 53.3 - 92.4%) and 39 % (C.I., 21.7 - 56.6%) for the capsule and tablet respectively and the difference was significant (P < 0.05).",Absolute bioavailability of quinine formulations in Nigeria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15819461/),%,73,240815,DB00468,Quinine
,15819461,absolute bioavailability (F),"The absolute bioavailability (F) were 73% (C.l., 53.3 - 92.4%) and 39 % (C.I., 21.7 - 56.6%) for the capsule and tablet respectively and the difference was significant (P < 0.05).",Absolute bioavailability of quinine formulations in Nigeria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15819461/),%,39,240816,DB00468,Quinine
,12185554,fever clearance time,The median (range) fever clearance time was 51 h (4-152 h) and mean (SD) parasite clearance time was 74+/-28 h.,Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),h,51,240942,DB00468,Quinine
,12185554,parasite clearance time,The median (range) fever clearance time was 51 h (4-152 h) and mean (SD) parasite clearance time was 74+/-28 h.,Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),h,74,240943,DB00468,Quinine
,12185554,times to maximum concentrations,"The overall median times to maximum concentrations of quinine and its main metabolite 3-hydroxyquinine were 1.5 days and 4.0 days, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),d,1.5,240944,DB00468,Quinine
,12185554,times to maximum concentrations,"The overall median times to maximum concentrations of quinine and its main metabolite 3-hydroxyquinine were 1.5 days and 4.0 days, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),d,4.0,240945,DB00468,Quinine
,12185554,area under the plasma drug concentration-time curve to day 7 (AUC(0-7)),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[μg] / [d·ml],67.0,240946,DB00468,Quinine
,12185554,area under the plasma drug concentration-time curve to day 7 (AUC(0-7)),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[μg] / [d·ml],51.3,240947,DB00468,Quinine
,12185554,AUC(0-7),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[μg] / [d·ml],6.2,240948,DB00468,Quinine
,12185554,AUC(0-7),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[μg] / [d·ml],4.8,240949,DB00468,Quinine
,8443039,peak plasma concentrations,"2. Primaquine was rapidly absorbed, attaining peak plasma concentrations (median and range) of 167 (113-532) micrograms l-1 in 2 (1-4) h.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],167,242272,DB00468,Quinine
,8443039,apparent terminal half-life,"Thereafter, concentrations declined rapidly with an apparent terminal half-life of 6.1 (1.7-16.1) h and an oral clearance (CLpo) of 33.1 (17.6-49.3) l h-1.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,6.1,242273,DB00468,Quinine
,8443039,oral clearance (CLpo),"Thereafter, concentrations declined rapidly with an apparent terminal half-life of 6.1 (1.7-16.1) h and an oral clearance (CLpo) of 33.1 (17.6-49.3) l h-1.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[l] / [h],33.1,242274,DB00468,Quinine
,8443039,Cmax,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],229,242275,DB00468,Quinine
,8443039,tmax,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,3,242276,DB00468,Quinine
,8443039,"t1/2,z","Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,3.9,242277,DB00468,Quinine
,8443039,CLpo,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[l] / [h],34.0,242278,DB00468,Quinine
,8443039,maximum concentrations,3. The carboxylic acid metabolite of primaquine achieved maximum concentrations (median and range) of 890 (553-3634) micrograms l-1 at 6 (3-16) h.,"Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],890,242279,DB00468,Quinine
,8443039,"AUC (0,24 h)","AUC (0,24 h) was 12737 (6837-27388) micrograms l-1 h.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[h·μg] / [l],12737,242280,DB00468,Quinine
,8443039,Cmax,"Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],1035,242281,DB00468,Quinine
,8443039,tmax,"Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,8,242282,DB00468,Quinine
,8443039,"AUC(0,24)","Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[h·μg] / [l],13471,242283,DB00468,Quinine
,12435698,time to the maximum concentration of drug,"ARS was rapid, with the maximum concentration of DHA in serum being achieved in less than 1 h in most children (median time to the maximum concentration of drug in serum, 35.1 min; range, 10.8 to 71.9 min).",Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12435698/),min,35.1,242401,DB00468,Quinine
,12435698,absolute bioavailability,"The absolute bioavailability of DHA was a median of 86.4% (range, 11.4 to 462.1%), the median steady-state volume of distribution was 1.3 liters/kg (range, 0.5 to 7.9 liters/kg), and the median clearance was 0.028 liters/kg/min (range, 0.001 to 1.58 liters/kg/min).",Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12435698/),%,86.4,242402,DB00468,Quinine
,12435698,steady-state volume of distribution,"The absolute bioavailability of DHA was a median of 86.4% (range, 11.4 to 462.1%), the median steady-state volume of distribution was 1.3 liters/kg (range, 0.5 to 7.9 liters/kg), and the median clearance was 0.028 liters/kg/min (range, 0.001 to 1.58 liters/kg/min).",Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12435698/),[l] / [kg],1.3,242403,DB00468,Quinine
,12435698,clearance,"The absolute bioavailability of DHA was a median of 86.4% (range, 11.4 to 462.1%), the median steady-state volume of distribution was 1.3 liters/kg (range, 0.5 to 7.9 liters/kg), and the median clearance was 0.028 liters/kg/min (range, 0.001 to 1.58 liters/kg/min).",Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12435698/),[l] / [kg·min],0.028,242404,DB00468,Quinine
,22629364,inhibition concentration 50% (IC(50)),Here we show that FBS0701 has inhibition concentration 50% (IC(50)) of 6 µM for Plasmodium falciparum in contrast to the IC(50) for deferiprone and deferoxamine at 15 and 30 µM respectively.,"Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22629364/),μM,6,244824,DB00468,Quinine
,22629364,IC(50),Here we show that FBS0701 has inhibition concentration 50% (IC(50)) of 6 µM for Plasmodium falciparum in contrast to the IC(50) for deferiprone and deferoxamine at 15 and 30 µM respectively.,"Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22629364/),μM,15,244825,DB00468,Quinine
,22629364,IC(50),Here we show that FBS0701 has inhibition concentration 50% (IC(50)) of 6 µM for Plasmodium falciparum in contrast to the IC(50) for deferiprone and deferoxamine at 15 and 30 µM respectively.,"Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22629364/),μM,30,244826,DB00468,Quinine
,2049234,Cmax,There were no significant differences (P greater than 0.05) in the maximum plasma concentration (Cmax) and the time of peak concentration (tmax) between the subjects who used oral contraceptives (Cmax = 5.3 +/- 1.0 (s.d.) mg l-1; tmax = 1.4 +/- 0.7 h) and the control subjects (Cmax = 5.6 +/- 0.9 mg l-1; tmax = 2.1 +/- 0.9 h).,Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),[mg] / [l],5.3,245004,DB00468,Quinine
,2049234,tmax,There were no significant differences (P greater than 0.05) in the maximum plasma concentration (Cmax) and the time of peak concentration (tmax) between the subjects who used oral contraceptives (Cmax = 5.3 +/- 1.0 (s.d.) mg l-1; tmax = 1.4 +/- 0.7 h) and the control subjects (Cmax = 5.6 +/- 0.9 mg l-1; tmax = 2.1 +/- 0.9 h).,Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),h,1.4,245005,DB00468,Quinine
,2049234,Cmax,There were no significant differences (P greater than 0.05) in the maximum plasma concentration (Cmax) and the time of peak concentration (tmax) between the subjects who used oral contraceptives (Cmax = 5.3 +/- 1.0 (s.d.) mg l-1; tmax = 1.4 +/- 0.7 h) and the control subjects (Cmax = 5.6 +/- 0.9 mg l-1; tmax = 2.1 +/- 0.9 h).,Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),[mg] / [l],5.6,245006,DB00468,Quinine
,2049234,tmax,There were no significant differences (P greater than 0.05) in the maximum plasma concentration (Cmax) and the time of peak concentration (tmax) between the subjects who used oral contraceptives (Cmax = 5.3 +/- 1.0 (s.d.) mg l-1; tmax = 1.4 +/- 0.7 h) and the control subjects (Cmax = 5.6 +/- 0.9 mg l-1; tmax = 2.1 +/- 0.9 h).,Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),h,2.1,245007,DB00468,Quinine
,2049234,elimination half-life,The mean elimination half-life of quinine in the oral contraceptives user group (12.5 +/- 1.9 h) was similar (P greater than 0.05) to that in the control group (11.8 +/- 2.7 h).,Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),h,12.5,245008,DB00468,Quinine
,2049234,elimination half-life,The mean elimination half-life of quinine in the oral contraceptives user group (12.5 +/- 1.9 h) was similar (P greater than 0.05) to that in the control group (11.8 +/- 2.7 h).,Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),h,11.8,245009,DB00468,Quinine
,2049234,oral clearance,"The oral clearance of quinine in the oral contraceptive user group was 0.133 +/- 0.055 l h-1 kg-1 (range 0.073-0.233) and was not significantly different (P greater than 0.05) from that observed in the control group (0.125 +/- 0.025 l h-1 kg-1, range 0.075-0.148).",Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),[l] / [h·kg],0.133,245010,DB00468,Quinine
,2049234,oral clearance,"The oral clearance of quinine in the oral contraceptive user group was 0.133 +/- 0.055 l h-1 kg-1 (range 0.073-0.233) and was not significantly different (P greater than 0.05) from that observed in the control group (0.125 +/- 0.025 l h-1 kg-1, range 0.075-0.148).",Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049234/),[l] / [h·kg],0.125,245011,DB00468,Quinine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],8.7,247154,DB00468,Quinine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],6.0,247155,DB00468,Quinine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247156,DB00468,Quinine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],19,247157,DB00468,Quinine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247158,DB00468,Quinine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],30,247159,DB00468,Quinine
,11417441,elimination half-life,The median (range) quinine elimination half-life was significantly shorter after a high-salt diet [8.5 (4.3-10.2) h] than after a low-salt diet [10.0 (7.6-14.8) h] (P = 0.04).,Oral quinine pharmacokinetics and dietary salt intake. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417441/),h,8.5,248325,DB00468,Quinine
,11417441,elimination half-life,The median (range) quinine elimination half-life was significantly shorter after a high-salt diet [8.5 (4.3-10.2) h] than after a low-salt diet [10.0 (7.6-14.8) h] (P = 0.04).,Oral quinine pharmacokinetics and dietary salt intake. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417441/),h,10.0,248326,DB00468,Quinine
,17089111,Cmax,"Median (range) observed DHA Cmax was 2128 (513-5789) nmol/L, elimination half-life was 0.34 (0.14-0.87) h, and the time to the last detectable DHA was 2 h.",The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089111/),[nM] / [l],2128,249889,DB00468,Quinine
,17089111,elimination half-life,"Median (range) observed DHA Cmax was 2128 (513-5789) nmol/L, elimination half-life was 0.34 (0.14-0.87) h, and the time to the last detectable DHA was 2 h.",The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089111/),h,0.34,249890,DB00468,Quinine
,17089111,time to the last detectable,"Median (range) observed DHA Cmax was 2128 (513-5789) nmol/L, elimination half-life was 0.34 (0.14-0.87) h, and the time to the last detectable DHA was 2 h.",The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089111/),h,2,249891,DB00468,Quinine
,3256106,volumes of the central compartment,Both the volumes of the central compartment (mean +/- SD: 0.17 +/- 0.10 litre/kg) and total volumes of distribution (0.74 +/- 0.30 litre/kg) were significantly smaller than those previously reported for healthy subjects.,Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3256106/),[l] / [kg],0.17,252505,DB00468,Quinine
,3256106,total volumes of distribution,Both the volumes of the central compartment (mean +/- SD: 0.17 +/- 0.10 litre/kg) and total volumes of distribution (0.74 +/- 0.30 litre/kg) were significantly smaller than those previously reported for healthy subjects.,Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3256106/),[l] / [kg],0.74,252506,DB00468,Quinine
,3256106,distribution half-time,"Further reductions in administration time would produce disproportionately higher plasma quinine concentrations, especially as the distribution half-time (2.3 +/- 3.2 min) is approached.",Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3256106/),min,2.3,252507,DB00468,Quinine
less,16127036,C50,"The C50 distribution was unimodal, and all C50 values were less than 8 mg/liter, while Cav ranged from 5.9 to 18.3 mg/liter.",Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127036/),[mg] / [l],8,253672,DB00468,Quinine
,16127036,Cav,"The C50 distribution was unimodal, and all C50 values were less than 8 mg/liter, while Cav ranged from 5.9 to 18.3 mg/liter.",Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127036/),[mg] / [l],5.9 to 18.3,253673,DB00468,Quinine
,16127036,Ter,"The median (10th to 90th percentile) Ter was 47 h (range, 39 to 76 h).",Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127036/),h,47,253674,DB00468,Quinine
,10952483,maximum concentration,"After oral administration, hydroquinine was rapidly absorbed (mean +/- SD: maximum concentration 2.43+/-0.68 mg/ 1; time to maximum concentration 1.4+/-1.2 h; lag time 0.54+/-0.50 h).",Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),mg,2.43,255375,DB00468,Quinine
,10952483,time to maximum concentration,"After oral administration, hydroquinine was rapidly absorbed (mean +/- SD: maximum concentration 2.43+/-0.68 mg/ 1; time to maximum concentration 1.4+/-1.2 h; lag time 0.54+/-0.50 h).",Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),h,1.4,255376,DB00468,Quinine
,10952483,lag time,"After oral administration, hydroquinine was rapidly absorbed (mean +/- SD: maximum concentration 2.43+/-0.68 mg/ 1; time to maximum concentration 1.4+/-1.2 h; lag time 0.54+/-0.50 h).",Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),h,0.54,255377,DB00468,Quinine
,10952483,elimination half-life,"With an elimination half-life of 10.9+/-6.1 h, steady-state was reached in several days.",Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),h,10.9,255378,DB00468,Quinine
,10952483,distribution volume,"The distribution volume was 1.24+/-0.29 l/kg, total clearance was 6.7+/-3.2 l/h.",Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),[l] / [kg],1.24,255379,DB00468,Quinine
,10952483,total clearance,"The distribution volume was 1.24+/-0.29 l/kg, total clearance was 6.7+/-3.2 l/h.",Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),[l] / [h],6.7,255380,DB00468,Quinine
,10952483,unbound hydroquinine fraction,The measured unbound hydroquinine fraction was 8.6+/-3.0%.,Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),%,8.6,255381,DB00468,Quinine
,10952483,Cumulative,Cumulative urinary excretion of unchanged hydroquinine 24 h after the first dose was 35.5+/-9.2 mg.,Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),mg,35.5,255382,DB00468,Quinine
,10952483,urinary excretion,Cumulative urinary excretion of unchanged hydroquinine 24 h after the first dose was 35.5+/-9.2 mg.,Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952483/),mg,35.5,255383,DB00468,Quinine
,22352317,hepatic clearance,"The in vivo findings were supported by the result from the test phase where hepatic clearance (4.3 mL min⁻¹ kg⁻¹) was decreased by 29% (metabolism inhibition), 43% (transport inhibition) and 57% (metabolism + transport inhibition).",The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352317/),kg⁻¹·min⁻¹·ml,4.3,255723,DB00468,Quinine
,12659609,maximum serum concentration,Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.,Toxicity related to chloroquine treatment of resistant vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659609/),[μg] / [l],902,256908,DB00468,Quinine
,8703656,tmax,"tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1-5] vs 1.6 [0.8-2] h; t1/2,z 23.4 [17.4-41.7] vs 9.7 [7.8-17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33-15.87] vs 2.78 [1.49-3.38] 1 kg-1).",Pharmacokinetics of quinine in chronic liver disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703656/),h,2,259591,DB00468,Quinine
,8703656,tmax,"tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1-5] vs 1.6 [0.8-2] h; t1/2,z 23.4 [17.4-41.7] vs 9.7 [7.8-17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33-15.87] vs 2.78 [1.49-3.38] 1 kg-1).",Pharmacokinetics of quinine in chronic liver disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703656/),h,1.6,259592,DB00468,Quinine
,8703656,"t1/2,z","tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1-5] vs 1.6 [0.8-2] h; t1/2,z 23.4 [17.4-41.7] vs 9.7 [7.8-17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33-15.87] vs 2.78 [1.49-3.38] 1 kg-1).",Pharmacokinetics of quinine in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703656/),h,23.4,259593,DB00468,Quinine
,8703656,"t1/2,z","tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1-5] vs 1.6 [0.8-2] h; t1/2,z 23.4 [17.4-41.7] vs 9.7 [7.8-17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33-15.87] vs 2.78 [1.49-3.38] 1 kg-1).",Pharmacokinetics of quinine in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703656/),h,9.7,259594,DB00468,Quinine
,8703656,Vz/F,"tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1-5] vs 1.6 [0.8-2] h; t1/2,z 23.4 [17.4-41.7] vs 9.7 [7.8-17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33-15.87] vs 2.78 [1.49-3.38] 1 kg-1).",Pharmacokinetics of quinine in chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703656/),[1] / [kg],4.21,259595,DB00468,Quinine
,8703656,Vz/F,"tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1-5] vs 1.6 [0.8-2] h; t1/2,z 23.4 [17.4-41.7] vs 9.7 [7.8-17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33-15.87] vs 2.78 [1.49-3.38] 1 kg-1).",Pharmacokinetics of quinine in chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703656/),[1] / [kg],2.78,259596,DB00468,Quinine
,32021159,zeta potential,"The formulations showed a nanometric range (between 138 ± 3.8 to 201 ± 23.0 nm), zeta potential (mV) of -33.1 ± 0.7 (NCP80), -30.5 ± 1 (UNCP80), -25.5 ± 1 (NSP80), -20 ± 0.3 (UNSP80), 4.61 ± 1 (NCEUD), 14.1 ± 0.9 (UNCEUD), 2.86 ± 0.3 (NSEUD) and 2.84 ± 0.6 (UNSEUD), content close to 100%, and good QN protection against UVA light.",Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32021159/),mv,33.1,262865,DB00468,Quinine
,32021159,zeta potential,"The formulations showed a nanometric range (between 138 ± 3.8 to 201 ± 23.0 nm), zeta potential (mV) of -33.1 ± 0.7 (NCP80), -30.5 ± 1 (UNCP80), -25.5 ± 1 (NSP80), -20 ± 0.3 (UNSP80), 4.61 ± 1 (NCEUD), 14.1 ± 0.9 (UNCEUD), 2.86 ± 0.3 (NSEUD) and 2.84 ± 0.6 (UNSEUD), content close to 100%, and good QN protection against UVA light.",Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32021159/),mv,30.5,262866,DB00468,Quinine
,32021159,zeta potential,"The formulations showed a nanometric range (between 138 ± 3.8 to 201 ± 23.0 nm), zeta potential (mV) of -33.1 ± 0.7 (NCP80), -30.5 ± 1 (UNCP80), -25.5 ± 1 (NSP80), -20 ± 0.3 (UNSP80), 4.61 ± 1 (NCEUD), 14.1 ± 0.9 (UNCEUD), 2.86 ± 0.3 (NSEUD) and 2.84 ± 0.6 (UNSEUD), content close to 100%, and good QN protection against UVA light.",Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32021159/),mv,25.5,262867,DB00468,Quinine
,32021159,zeta potential,"The formulations showed a nanometric range (between 138 ± 3.8 to 201 ± 23.0 nm), zeta potential (mV) of -33.1 ± 0.7 (NCP80), -30.5 ± 1 (UNCP80), -25.5 ± 1 (NSP80), -20 ± 0.3 (UNSP80), 4.61 ± 1 (NCEUD), 14.1 ± 0.9 (UNCEUD), 2.86 ± 0.3 (NSEUD) and 2.84 ± 0.6 (UNSEUD), content close to 100%, and good QN protection against UVA light.",Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32021159/),mv,4.61,262868,DB00468,Quinine
,32021159,zeta potential,"The formulations showed a nanometric range (between 138 ± 3.8 to 201 ± 23.0 nm), zeta potential (mV) of -33.1 ± 0.7 (NCP80), -30.5 ± 1 (UNCP80), -25.5 ± 1 (NSP80), -20 ± 0.3 (UNSP80), 4.61 ± 1 (NCEUD), 14.1 ± 0.9 (UNCEUD), 2.86 ± 0.3 (NSEUD) and 2.84 ± 0.6 (UNSEUD), content close to 100%, and good QN protection against UVA light.",Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32021159/),mv,14.1,262869,DB00468,Quinine
,32021159,zeta potential,"The formulations showed a nanometric range (between 138 ± 3.8 to 201 ± 23.0 nm), zeta potential (mV) of -33.1 ± 0.7 (NCP80), -30.5 ± 1 (UNCP80), -25.5 ± 1 (NSP80), -20 ± 0.3 (UNSP80), 4.61 ± 1 (NCEUD), 14.1 ± 0.9 (UNCEUD), 2.86 ± 0.3 (NSEUD) and 2.84 ± 0.6 (UNSEUD), content close to 100%, and good QN protection against UVA light.",Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32021159/),mv,2.86,262870,DB00468,Quinine
,32021159,zeta potential,"The formulations showed a nanometric range (between 138 ± 3.8 to 201 ± 23.0 nm), zeta potential (mV) of -33.1 ± 0.7 (NCP80), -30.5 ± 1 (UNCP80), -25.5 ± 1 (NSP80), -20 ± 0.3 (UNSP80), 4.61 ± 1 (NCEUD), 14.1 ± 0.9 (UNCEUD), 2.86 ± 0.3 (NSEUD) and 2.84 ± 0.6 (UNSEUD), content close to 100%, and good QN protection against UVA light.",Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32021159/),mv,2.84,262871,DB00468,Quinine
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,2.6,263341,DB00468,Quinine
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,5.1,263342,DB00468,Quinine
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,7.01,263343,DB00468,Quinine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[h·ng] / [ml],6470,266472,DB00468,Quinine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[h·ng] / [ml],3822,266473,DB00468,Quinine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[h·ng] / [ml],6642,266474,DB00468,Quinine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[h·ng] / [ml],4808,266475,DB00468,Quinine
,1979624,clearance (CL),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [g·min],0.33,266476,DB00468,Quinine
,1979624,clearance (CL),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [g·min],0.64,266477,DB00468,Quinine
,1979624,volume of distribution (Vd),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [g],53.0,266478,DB00468,Quinine
,1979624,volume of distribution (Vd),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [g],81.2,266479,DB00468,Quinine
,1979624,elimination half-life (t1/2),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),h,1.93,266480,DB00468,Quinine
,1979624,elimination half-life (t1/2),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),h,1.37,266481,DB00468,Quinine
,1979624,CL,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,0.38,266482,DB00468,Quinine
,1979624,CL,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,0.64,266483,DB00468,Quinine
,1979624,t1/2,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,1.62,266484,DB00468,Quinine
,1979624,t1/2,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,0.88,266485,DB00468,Quinine
,26693810,metabolic ratio,"Patients with optimal response to imatinib after 12 months of therapy did not differ in CYP3A activity compared to nonoptimal responders (quinine metabolic ratio of 14.69 and 14.70, respectively; P = 0.966).",In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26693810/),,14.69,266876,DB00468,Quinine
,26693810,metabolic ratio,"Patients with optimal response to imatinib after 12 months of therapy did not differ in CYP3A activity compared to nonoptimal responders (quinine metabolic ratio of 14.69 and 14.70, respectively; P = 0.966).",In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26693810/),,14.,266877,DB00468,Quinine
,8527275,clearance (CL/F),The mean (+/- s.d.) clearance (CL/F) of quinine coadministered with rifampicin (0.87 +/- 0.35 1 h-1 kg-1) was significantly greater than that of quinine alone (0.14 +/- 0.05 1 h-1 kg-1).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],0.87,269358,DB00468,Quinine
,8527275,clearance (CL/F),The mean (+/- s.d.) clearance (CL/F) of quinine coadministered with rifampicin (0.87 +/- 0.35 1 h-1 kg-1) was significantly greater than that of quinine alone (0.14 +/- 0.05 1 h-1 kg-1).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],0.14,269359,DB00468,Quinine
,8527275,unbound clearance (CLu/F),"The unbound clearance (CLu/F) of quinine, which reflects the activity of the drug-metabolizing enzymes, was considerably greater (6.9-fold) in subjects when rifampicin was coadministered with quinine than that of quinine alone (6.9 +/- 3.6 vs 1.0 +/- 0.5 1 h-1 kg-1; the 95% C.I. for the mean difference was 3.3 to 8.5).",Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],6.9,269360,DB00468,Quinine
,8527275,unbound clearance (CLu/F),"The unbound clearance (CLu/F) of quinine, which reflects the activity of the drug-metabolizing enzymes, was considerably greater (6.9-fold) in subjects when rifampicin was coadministered with quinine than that of quinine alone (6.9 +/- 3.6 vs 1.0 +/- 0.5 1 h-1 kg-1; the 95% C.I. for the mean difference was 3.3 to 8.5).",Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],1.0,269361,DB00468,Quinine
,8527275,elimination half-life,The mean elimination half-life of quinine when coadministered with rifampicin (5.5 +/- 3.0 h) was significantly shorter than when quinine was given alone (11.1 +/- 3.0 h; the 95% C.I. for the mean difference was -8.6 to -2.6).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),h,5.5,269362,DB00468,Quinine
,8527275,elimination half-life,The mean elimination half-life of quinine when coadministered with rifampicin (5.5 +/- 3.0 h) was significantly shorter than when quinine was given alone (11.1 +/- 3.0 h; the 95% C.I. for the mean difference was -8.6 to -2.6).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),h,11.1,269363,DB00468,Quinine
